Biodegradable polymeric delivery systems for protein subunit vaccines by Heffernan, Michael John
BIODEGRADABLE POLYMERIC DELIVERY SYSTEMS FOR 



























In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 








Georgia Institute of Technology 
August 2008 
BIODEGRADABLE POLYMERIC DELIVERY SYSTEMS FOR 


























Approved by:   
   
Dr. Niren Murthy, Advisor 
School of Biomedical Engineering 
Georgia Institute of Technology 
 Dr. Ravi Bellamkonda 
School of Biomedical Engineering 
Georgia Institute of Technology 
   
Dr. J. Carson Meredith 
School of Chemical and Biomolecular 
Engineering 
Georgia Institute of Technology 
 Dr. Mark R. Prausnitz 
School of Chemical and Biomolecular 
Engineering 
Georgia Institute of Technology 
   
Dr. Julia E. Babensee 
School of Biomedical Engineering 
Georgia Institute of Technology 
 
  
   



















To my beautiful and loving wife, Kasey, 









 I wish to thank my advisor, Dr. Niren Murthy, for his guidance and support in my 
Ph.D. studies.  Niren has been a great source of knowledge and ingenuity in the fields of 
chemistry, bioengineering, and drug delivery, and his enthusiasm has helped me to 
accomplish what I may not have thought was possible.  He has taken the time to give 
career advice, and he gave me the flexibility to pursue projects of my interest while 
keeping me focused on the research goals. 
 I thank all the members of our laboratory, past and present:  Stephen Yang, 
Rebecca Guinn, Jihua Hao, Siraj Khaja, Scott Wilson, Sungmun Lee, Madhuri Dasari, 
Dongwon Lee, Venkata Reddy Erigala, Kousik Kundu, Jay Sy, Chen-Yu Kao, Ben 
Solomon, and Sydney Shaffer.  The group has been an extended family to me, and you 
have all helped me in so many ways in my research and with emotional support.  Steve 
and I shared many experiences together as classmates and co-workers, and he and Cindy 
have been great friends to us.  I wish the best for everyone in the Murthy lab and your 
families in your future endeavors. 
 I wish to thank our collaborators for their many contributions to this research:  Dr. 
Bali Pulendran of the Emory Vaccine Center, for supporting our vaccine delivery projects 
and providing reference letters; Marcin Kwissa, for his contributions to the micelle 
vaccine project by conducting several in vitro and animal studies; Sudhir Kasturi, for his 
great help during the last two years on the vaccine project, for his assistance in 
formulating and testing the polyketal microparticles and in training me on the 
immunological assays;  Dr. Robert Pierce, for his collaboration while at the University of 
 v
Rochester and for his reference letters, and his lab members Judith Cornejo, Jessica 
Spahn, and Mahesh Bhide for their contributions toward gathering in vivo data on the 
polyketals; and all of our collaborators who have helped with the polyketal projects. 
 I thank the members of my thesis committee for their guidance and advice, and all 
the professors whose classes I took, for their dedication to teaching.  Many thanks also to 
the BME and IBB staff, who gave us a top-notch environment to conduct research; to the 
NeuroLab for the use of equipment; and to all those who have given me career advice and 
reference letters. 
 I am also grateful for the various funding sources that have made this research 
possible:  The Parker H. Petit Institute for Bioengineering and Bioscience, the Georgia 
Tech/Emory Center for the Engineering of Living Tissues, the National Science 
Foundation, the National Institutes of Health, a J&J/GT Health Care Innovation Seed 
Grant, an NSF Graduate Research Fellowship, and a GAANN fellowship through the 
Center for Drug Design, Development, and Delivery (CD4). 
 Many thanks to all of my friends in the IBB building, BME department, and 
B2UGS organization:  Udita and Pranjal Adurkar, Sarah Tressel, Kartik Sundareswaran, 
Kartik Sundar, Mamta and Pritty Patel, Abhiruchi Agarwal (and Ankit), for watching our 
kids and for all the fun potlucks; my fellow B2UGS co-chairs Prerona Chakravarty and 
Derek Doroski, and Shawna Garcia, for working together on Education and Outreach 
events; and all the others who have given me a smile or word of encouragement in the 
hallway or in wing 3A, and all those who have helped me with an experiment or lent me 
a reagent.  I thank my longtime friend Hanno for giving me a place to stay in downtown 
Atlanta and for encouraging me to run a half-marathon at age thirty-eight. 
 vi
 I would like to thank all of our fellow parishioners at St. Andrew Catholic Church 
in Roswell, especially my “brothers” in the Christ Renews His Parish program and fellow 
scout leaders, who have inspired me and helped me grow in my faith in the past few 
years; Msgr. Hugh Marren, Fr. Michael Sherliza, and the other priests and deacons, for 
your inspirational homilies that were always just what I needed to hear, and for bringing 
the gift of the Eucharist to us each Mass; Fr. Mario Di Lella, for providing Adoration of 
the Blessed Sacrament at the campus Catholic Center.  I also give thanks to the many 
saints of the Church who have inspired me through their works and teachings. 
 I thank my Mom and Dad for instilling in me a strong work ethic and a love of 
learning and teaching, for their love and support during this time, for all the times they 
have taken our boys into their care, and for their many prayers, which have helped bring 
me many blessings throughout the years.  I also thank my mother-in-law Shin Sook Lee 
and father-in-law Hyun Joon Lee, and my Aunt Sue and Uncle Dave, for their support 
and reassurance; and all of our family members, relatives, and friends for all their support 
and encouragement during my Ph.D. studies. 
 I would like to remember our dear family members who have departed from us 
during this period:  Shin Sook Lee, my mother-in-law; Madeline Lennert, my 
grandmother; Mr. Lee, my wife’s “uncle”, David A. Lennert, my uncle.  We miss you all 
so much. 
 I thank our three wonderful boys – Luke, Nathan, and Sean – for bringing so 
much joy into my life, in watching your unique talents and personalities unfold, and for 
bearing with my lengthy explanations about molecules, cells, and everything scientific.  I 
hope that you will be inspired to pursue your dreams some day, to follow your true 
 vii
calling.  I am truly proud to be your daddy, and I thank God for bringing you into this 
world. 
 I am truly grateful to my wife, Kasey, for her tireless support and efforts during 
these past five years, for all the encouragement she has given me in coming back to 
school and throughout the Ph.D. program.  Seven years ago, when we decided to embark 
on this journey, Kasey was willing to give up material comforts and a nice house, and 
move with three young children to a new city with a lot of uncertainties about our future 
and a substantial downsizing in our budget.  Kasey has done an amazing job at keeping 
our household running smoothly, managing of all the bills, keeping track of the family’s 
appointments, activities, birthdays, events, and many other details, not to mention all the 
time spent shopping, cleaning, and organizing, and providing delicious meals for our 
family, the list goes on.  She continued to do all of this work at home while taking on a 
full-time job in the last two years as well.  Kasey has stood by me every step of the way, 
through all the challenges we faced during this period, and I could not have done any of 
this without her.  She is my best friend and my soulmate, and she has consoled me on 
many occasions during the difficult times.  Kasey has so many talents and wonderful 
qualities, and I love her with all of my heart.  I thank God for bringing Kasey into my 
life, for the love that we share, and for guiding us on our spiritual journey together. 
 Finally, I give thanks to God the Father, Son, and Holy Spirit, my creator, savior, 
and counselor;  who makes all things possible.  This work is offered for His glory. 
 viii
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ............................................................................................ iv 
LIST OF FIGURES ......................................................................................................... ix 
LIST OF ABBREVIATIONS ........................................................................................ xii 
SUMMARY ..................................................................................................................... xv 
CHAPTER 1:  INTRODUCTION................................................................................... 1 
1.1  Motivation............................................................................................................... 1 
1.2  Research Objectives and Specific Aims ............................................................... 5 
1.3  Review of Relevant Literature ............................................................................ 10 
CHAPTER 2:  DEVELOPMENT OF CROSS-LINKED BLOCK COPOLYMER 
MICELLES ..................................................................................................................... 19 
2.1  Introduction.......................................................................................................... 19 
2.2  Experimental Methods ........................................................................................ 22 
2.3  Results ................................................................................................................... 27 
2.4  Discussion.............................................................................................................. 32 
CHAPTER 3:  DEVELOPMENT OF POLYKETAL MICROPARTICLES .......... 34 
3.1  Introduction.......................................................................................................... 34 
3.2  Experimental Methods ........................................................................................ 40 
3.3  Results ................................................................................................................... 50 
3.4  Discussion.............................................................................................................. 59 
CHAPTER 4:  EFFICACY OF MICROPARTICLE VACCINES CONTAINING 
OVALBUMIN AND IMMUNOSTIMULATORY AGENTS ..................................... 63 
4.1  Introduction.......................................................................................................... 63 
4.2  Experimental Methods ........................................................................................ 64 
4.3  Results ................................................................................................................... 68 
4.4  Discussion.............................................................................................................. 82 
CHAPTER 5:  CONCLUSIONS AND FUTURE DIRECTIONS .............................. 88 
5.1  Conclusions ........................................................................................................... 88 
5.2  Future Directions ................................................................................................. 89 
APPENDIX A.  MATERIALS AND SUPPLIES ......................................................... 93 
REFERENCES................................................................................................................ 96 
 ix
LIST OF FIGURES 
Page 
Figure 1.1.  Cross-linked micelle delivery system for proteins and nucleic acids. 7 
Figure 1.2.  Polyketal-based delivery system for proteins, nucleic acids, and hydrophobic 
molecules. 8 
Figure 2.1.  Schematic of polyion comlex (PIC) micelle self-assembly. 20 
Figure 2.2.  PEG-poly(lysine-dithiopyridyl) (PEG-PLTP) block copolymer. 24 
Figure 2.3.  Cross-linked copolymer micelle encapsulating protein antigen and Poly(I:C). 
  25 
Figure 2.4.  Agarose gel of cross-linked copolymer micelles with ovalbumin, CpG DNA, 
and poly(I:C). 27 
Figure 2.5.  SDS-PAGE (4-20%) of SPDP-Ova/CpG micelles. 28 
Figure 2.6.  Agarose gel of SPDP-Ova/CpG micelles. 29 
Figure 2.7.  Characterization of SPDP-Ova/CpG micelles by dynamic light scattering 
(DLS). 29 
Figure 2.8.  Characterization of SPDP-Ova/CpG micelles by atomic force microscopy 
(AFM). 30 
Figure 2.9.  SDS-PAGE (4-20%) of SPDP-FITC-Catalase micelles. 31 
Figure 3.1.  Synthesis of a polyketal via the acetal exchange reaction. 37 
Figure 3.2.  Toxicity of degradation products of co-polyketal PK3. 38 
Figure 3.3.  Hydrophobic ion pairing of poly(I:C) to CTAB and ovalbumin to CTAB. 39 
Figure 3.4.  Synthesis of the polyketal, poly(1,4,-phenylene-acetone dimethylene 
ketal)(PPADK), via the acetal exchange reaction. 41 
Figure 3.5.  Synthesis of co-polyketal PK3 via the acetal exchange polymerization. 42 
Figure 3.6.  GPC trace of PPADK in THF. 50 
Figure 3.7.   1H NMR spectrum of PPADK in CDCl3. 51 
Figure 3.8.  Hydrolysis kinetics of PPADK. 52 
 x
Figure 3.9.   Release of rhodamine B from PCADK microparticles at room temperature.
 53 
Figure 3.10.  Release of fluorescein from PPADK nanoparticles. 54 
Figure 3.11.  Scanning electron microscope images of microparticles fabricated with 
PPADK and PK3/Ova/poly(I:C). 57 
Figure 3.12.  MTS cell viability assay for polyketal microparticles containing ovalbumin 
and/or poly(I:C). 58 
Figure 3.13.  MTS cell viability assay for soluble ovalbumin, poly(I:C), and CTAB. 58 
Figure 4.1.  In vitro protocol for dendritic cell cross-priming of OT-1 splenocytes. 66 
Figure 4.2.  Flow cytometry gating for surface CD8 and intracellular cytokines. 68 
Figure 4.3.  In vitro cross-priming of CD8+ T cells by micelles containing ovalbumin and 
CpG-DNA.  Vaccine-pulsed dendritic cells were co-cultured with total OT-1 
splenocytes. 69 
Figure 4.4.  In vitro cross-priming of CD8+ T cells by micelles containing ovalbumin and 
CpG-DNA.  Vaccine-pulsed dendritic cells were co-cultured with CD8+ OT-1 
splenocytes. 69 
Figure 4.5.  In vivo prime-boost vaccination by micelles containing ovalbumin and CpG-
DNA. 70 
Figure 4.6.  In vitro cross-priming of CD8+ T cells by micelles containing ovalbumin, 
CpG-DNA, and poly(I:C). 72 
Figure 4.7.  In vivo cross-priming of CD8+ T cells by micelles containing ovalbumin and 
CpG-DNA. 73 
Figure 4.8.  In vitro cross-priming of CD8+ T cells by hybrid polyketal/PLGA 
microparticles containing ovalbumin and MPL. 74 
Figure 4.9.  In vivo cross-priming of CD8+ T cells by hybrid polyketal/PLGA 
microparticles containing ovalbumin and MPL. 75 
Figure 4.10.  In vitro DC-OT1 cross-priming by polyketal(Ova-poly(I:C)) vaccine at 0.01 
µg/mL Ova; flow cytometry scatter plots for CD8+IFNγ+ cells. 77 
Figure 4.11.  In vitro DC-OT1 cross-priming by polyketal(Ova-poly(I:C)) vaccine; 
percentage of IFNγ-producing CD8+ cells. 78 
Figure 4.12.  In vitro DC-OT1 cross-priming by polyketal(Ova-poly(I:C)) vaccine; 
percentage of TNFα-producing CD8+ cells. 79 
 xi
Figure 4.13.  In vitro DC-OT1 cross-priming by polyketal(Ova-poly(I:C)) vaccine; 
percentage of IL-2-producing CD8+ cells. 80 
Figure 4.14.   In vivo cross-priming of CD8+ T cells by polyketal(Ova-poly(I:C)) vaccine.
 81 
 xii
LIST OF ABBREVIATIONS 
 
AFM Atomic force microscopy 
APC Antigen-presenting cell 
CD Cluster of differentiation 
CDM 1,4-Cyclohexanedimethanol 
CpG Cytidine-Guanidine motif found in bacterial DNA 
CTAB Cetyltrimethylammonium bromide 
CTL Cytotoxic T lymphocyte 
d.p. Degree of polymerization 
DAPI 4',6-Diamidino-2-phenylindole 
DC Dendritic cell 
DCl Deuterium chloride 
DCM Dichloromethane 






FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
FITC Fluorescein isothiocyanate 
FLT3 FMS-like tyrosine kinase 3 








MACS Magnetic-activated cell sorter 
MF59 A vaccine adjuvant 
MHC Major histocompatibility complex 
MPL Monophosphoryl lipid A 
MyD88 Myeloid differentiation factor 88 
NCA N-carboxyanhydride 
NMR Nuclear magnetic resonance 
OT-1 Transgenic mouse with expanded population of T cells specific 
to the ovalbumin peptide SIINFEKL 
Ova Ovalbumin (albumin from chicken egg) 
PAGE Polyacrylamide gel electrophoresis 
PAMP Pathogen-associated molecular pattern 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate-buffered saline 
PDTEA Pyridyldithioethylacrylate 
PEG Poly(ethylene glycol) 
PIC Polyion complex 
PK Polyketal 
PKN Polyketal nanoparticle 
PK3 Co-polyketal synthesized using 80% 1,4-cyclohexane 
dimethanol and 20% 1,5-pentanediol 
PLA, PLGA Poly(lactic acid), poly(lactic-co-glycolic acid) 
PLL Poly(L-lysine) 
PLTP Poly(L-lysine-dithiopyridyl) 
Poly(I:C) Poly(riboinosinic acid)-poly(ribocytidylic acid) 
PPADK poly(1,4-phenylene-acetonedimethylene ketal) 
PVS Poly(vinyl sulfate) 
SDS Sodium dodecyl sulfate 
SEM Scanning electron microscopy/microscope 
SIINFEKL Octapeptide with sequence Ser-Ile-Ile-Asn-Phe-Glu-Lys-Leu 
SPDP Succinimidyl-pyridyl-dithio-proprionate 
 xiv
TH1 T-helper 1 
THF Tetrahydrofuran 
TIR Toll-IL-1 receptor 
TRAM TRIF-related adaptor molecule 
TRIF TIR domain containing adaptor inducing IFN-β 
TLR Toll-like receptor 






 Viral infections and cancer are major causes of death and disability worldwide, 
and new vaccine strategies are needed for preventive and therapeutic vaccines.  While 
traditional vaccines derived from attenuated or inactivated viruses have been successful 
in immunizing populations against certain infectious diseases, there are currently no 
approved vaccines for certain pathogens such as HIV, hepatitis C virus, and malaria, or 
for therapeutic treatment of most forms of cancer.  A promising strategy is the protein 
subunit vaccine, which is composed of purified protein antigens and immunostimulatory 
adjuvants.  The most widely studied adjuvants are agonists for Toll-like receptors 
(TLRs), which are expressed in antigen-presenting cells (APCs) and can recognize 
pathogen-associated molecular patterns.  Delivery of protein antigens and TLR agonists 
to APCs elicits cellular immunity through the generation of cytotoxic T lymphocytes.  
While many candidate delivery systems have been developed for protein/TLR vaccines, 
there is a need for further improvement with regard to the carrier materials and 
formulation methods, and through the utilization of new adjuvants, such as double-
stranded (ds)RNA (a TLR3 agonist).  The long-term objective of this research was to 
develop improved delivery vehicles for protein/TLR-based vaccines, guided by the 
central hypothesis that an effective vaccine delivery system would have stimulus-
responsive degradation and release, biodegradability into excretable non-acidic 
degradation products, and the ability to incorporate various TLR-inducing adjuvants.   
 The first two specific aims were centered around developing biodegradable 
polymeric delivery systems for protein antigens and TLR agonists, as model vaccine 
delivery systems.  In the first specific aim, we developed a cross-linked block copolymer 
 xvi
micelle for efficient encapsulation and retention of proteins, DNA, and RNA.  The 
micelle-based delivery system consists of a block copolymer of poly(ethylene glycol) 
(PEG) and poly(L-lysine), cross-linked by dithiopyridyl side groups to provide transport 
stability and intracellular release.  The focus of the second specific aim was to develop a 
pH-sensitive biodegradable polymer for fabricating microparticles encapsulating 
proteins/DNA/RNA and hydrophobic small molecules.  Using a new polymerization 
method based on the acetal exchange reaction, we synthesized hydrophobic, linear 
polymers containing pH-sensitive ketal linkages in the backbone.  This new polymer, 
termed a polyketal, has a combination of properties not found in existing drug delivery 
polymers, namely pH-sensitivity, biodegradability, ease of synthesis, and non-acidic 
degradation products.  Also, the technique of hydrophobic ion pairing was utilized to 
enhance the encapsulation of ovalbumin, DNA, and RNA in the polyketal microparticles 
via a single emulsion method.  In the third specific aim, we demonstrated that the 
micelle- and polyketal-based vaccine delivery systems enhanced the cross-priming of 
CD8+ T cells using in vitro and in vivo immunological models.  The model vaccines were 
composed of ovalbumin antigen and various TLR-inducing adjuvants including CpG-
DNA, monophosphoryl lipid A, and dsRNA.  The results demonstrate that the cross-
linked micelles and polyketal microparticles have considerable potential as delivery 






Viral infections and cancer are major causes of death and disability worldwide, 
and new strategies are greatly needed for preventive and therapeutic vaccines.  Treatment 
of these diseases requires vaccines that induce an adaptive immune response, specifically 
the generation of cytotoxic T lymphocytes which can eliminate virus-infected cells or 
tumors cells.  Traditional vaccines derived from attenuated or inactivated viruses have 
been successful in immunizing populations against certain infectious diseases such as 
polio, measles, and rubella.  However, there are currently no approved vaccines for 
certain pathogens such as HIV, hepatitis C virus, and malaria, or for therapeutic treatment 
of most forms of cancer (Kanzler 2007, Heit 2008).  Also, there is growing concern with 
preparedness for potential outbreaks such as influenza due to the long lead time in 
vaccine manufacturing by current processes.  There is thus a need for new vaccine 
strategies for preventive and therapeutic vaccines for cancers and infectious diseases. 
 A promising approach is the protein subunit vaccine, which is based on purified 
proteins derived from viruses or tumor cells (Bramwell 2005, Storni 2005).  Protein 
subunit vaccines have the potential to elicit an adaptive immune response specific to the 
pathogen or cancer cell.  Vaccines based on recombinant proteins can be manufactured 
on a large scale and would potentially have shorter lead times than current manufacturing 
processes such as egg-based cultures.  Also, protein-based vaccines do not carry the risk 
of infection as with live attenuated virus vaccines.  This is an important concern with 
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lethal viruses such as HIV.  Furthermore, there is flexibility in developing multivalent 
vaccines to improve efficacy against multi-clade viruses, such as HIV.  Multivalent 
vaccines could easily be formulated by combining proteins from different virus strains 
into a single vaccine or by tailoring the targeted strains to populations or individuals. 
 One important consideration with protein subunit vaccines is that proteins alone 
are weakly immunogenic and thus immunostimulatory adjuvants are required to boost 
their efficacy (Pashine 2005, Guy 2007).  The only approved adjuvant in the U.S. is alum, 
which consists of aluminum salts such as aluminum hydroxide or aluminum phosphate 
(Gupta 1998).  However, alum generally induces a T helper (TH)2-biased humoral 
(antibody) immune response as opposed to TH1-biased cellular (cytotoxic T cell) 
immunity (Lindblad 2004).  Thus there is a need for new adjuvants which stimulate a TH1 
response.  A widely studied class of immunostimulatory adjuvants being developed 
includes pathogen-derived molecules that are capable of stimulating innate immune 
responses through pathogen-associated molecular pattern (PAMP) recognition receptors 
such as the Toll-like receptors (TLRs) (Petrovsky 2004, Pashine 2005, Trinchieri 2007, 
Guy 2007). 
TLRs are expressed in antigen-presenting cells (APCs) and recognize 
characteristic molecules from pathogens, such as bacterial lipopolysaccharide (LPS) 
(TLR4) and bacterial and viral nucleic acids (TLRs 3, 7, and 9), as well as synthetic 
analogs of pathogen-derived molecules (Akira 2001, Takeda 2003, Ishii 2007).  
Treatment of APCs with agonists for TLR 3, 4, 7, and 9 leads to secretion of 
inflammatory cytokines such as Type I interferons, tumor necrosis factor (TNF)-α, 
interleukin (IL)-6, and IL-12, as well as upregulation of costimulatory surface molecules 
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such as CD80 and CD86 (Verdijk 1999, Alexopoulou 2001, Loré 2003, Napolitani 2005, 
Gautier 2005).  Also, the administration of protein antigens along with these TLR 
agonists to dendritic cells (DCs) enables the cross-priming of CD8+ T lymphocytes and 
the generation of an adaptive immune response with a CD4+ T helper 1 (TH1) bias. 
(Schulz 2005, Heit 2007, Zhang 2007, Standley 2007, Hamdy 2007).  Many formulations 
are in clinical development which utilize the TH1-inducing properties of TLR agonists 
(Kanzler 2007). 
A second major consideration with protein-based vaccines is the need for a 
delivery system which can target dendritic cells.  Proteins and nucleic acid TLR agonists 
are charged molecules which are not membrane-permeable and thus are not taken up 
effectively by DCs.  Considerable research has been reported on the development of 
microparticle-based vaccine delivery systems composed of poly(lactic-co-glycolic acid) 
(PLGA) and other polymers (Bramwell 2005, Jiang 2005, Storni 2005, Waeckerle-Man 
2005, and Tamber 2005).  These delivery systems typically target APCs via non-specific 
phagocytosis.  Vaccine delivery systems have been developed to deliver antigens for 
various infectious diseases and toxins, including anthrax, clostridium botulinum, ricin 
toxin, Marburg virus, Ebola virus, and tetanus, in addition to model antigens (Bramwell 
2005, Jiang 2005).  Microparticles also provide an advantage in that they enable 
simultaneous delivery of antigen and adjuvant to APCs.  Several studies have shown that 
injection of conjugated or co-encapsulated antigen/TLR ligand generates a stronger 
immune response than co-injection of separate antigen and TLR ligand (Cho 2000, 
Tafaghodi 2006, Kwon 2005b, Hamdy 2007, Heit 2007, Standley 2007, Zhang 2007).  
This is consistent with recent findings that the efficiency of major histocompatibility 
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complex (MHC) presentation of phagocytosed antigen is dependent on the presence of 
TLR ligand within the same phagosome (Blander 2006).   
Based on the objective of delivering protein antigen and immunostimulatory 
adjuvants to APCs, several design requirements can be identified for a protein vaccine 
delivery system.  The delivery vehicle should consist of a nano- or micro-scale particle 
which encapsulates protein antigen and adjuvants, and which is composed of 
biocompatible, degradable materials.  The vaccine should be easy to formulate and the 
carrier material should provide storage stability for the vaccine components.  It is also 
desirable to have a stimulus-responsive mechanism for intracellular release of the 
vaccine.  Finally, the formulation must have the flexibility of incorporating a variety of 
TLR agonists with different chemical properties. 
While many candidate delivery systems have been developed for protein/TLR 
vaccines, there is a need for further improvement with regard to the carrier materials and 
formulation methods, and through the utilization of new adjuvants.  For example, many 
of the microparticle systems are composed of PLGA and other polyesters, which have 
acidic degradation products.  This is a concern due to the potential for degradation of 
proteins or nucleic acids within the acidic microclimate inside degrading PLGA particles 
(Shenderova 1999, Fu 2000, Tamber 2005).  Also, many drug delivery polymers, 
including PLGA, do not exhibit stimulus-responsive release mechanisms, such as pH- or 
glutathione-sensitivity, which can selectively deliver therapeutic molecules to target cells.  
Certain delivery systems, such as acetal-crosslinked hydrogels, exhibit pH-sensitivity, 
however they are not composed of biodegradable polymers (Kwon 2005a, Kwon 2005b, 
Standley 2007). 
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There is also a need to expand the repertoire of available adjuvants in order to 
maximize the potential of protein-based vaccines.  Due to the variability in TLR 
expression among cell types and between species, different TLR agonists may be needed 
to target specific infectious diseases or cancers (Jarrossay 2001, Edwards 2003, Bagchi 
2007, Naik 2008).   For example, double-stranded (ds)RNA, a ligand for TLR3, is a 
strong inducer of a TH1 immune response and has shown promise as a vaccine adjuvant 
(Sloat 2006, Sloat 2008, Trumpfheller 2008).  TLR3 is an endosomal receptor, and thus 
delivery of dsRNA to the endosome would likely enhance engagement of TLR3 (Guy 
2007).  However, dsRNA has previously not been incorporated into microparticles, which 
are capable of endosomal delivery and thus could improve the efficacy of dsRNA as an 
adjuvant. 
 
1.2 Research Objectives and Specific Aims 
 The long-term objective of this research was to develop improved delivery 
vehicles for protein-based vaccines.  These improvements include new polymeric 
materials and formulation methods for encapsulating protein antigens and nucleic acid 
TLR agonists.  This work was guided by the central hypothesis that an effective vaccine 
delivery system would have the properties of stimulus-responsive degradation and 
release, biodegradability into excretable non-acidic degradation products, and the ability 
to incorporate various TLR-inducing adjuvants. 
 The first two specific aims were centered around developing biodegradable 
polymeric delivery systems for protein and nucleic acid therapeutics.  While the two 
delivery systems – cross-linked micelles and polyketal microparticles – have somewhat 
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different designs, both systems are capable of encapsulating proteins, DNA, and RNA.  
The third specific aim focuses on protein subunit vaccines, which is the primary 
application pursued in this thesis research.  In this aim, both of the delivery systems were 
used to formulate model vaccines that were evaluated using in vitro and animal models in 
collaboration with researchers at the Emory Vaccine Center.   
 
Specific Aim 1:  Develop a cross-linked block copolymer micelle for efficient 
encapsulation and retention of proteins, DNA, and RNA, as a model delivery system for 
protein-based vaccines. 
Hypothesis 1:  Efficient encapsulation and retention of proteins, DNA, and RNA can be 
achieved by optimizing the parameters governing self-assembly and cross-linking of a 
polyionic complex micelle delivery system.  
The micelle-based delivery system consists of a block copolymer of poly(ethylene 
glycol) (PEG) and poly(L-lysine), cross-linked by dithiopyridyl side groups to provide 
transport stability (Figure 1.1).  The PEG-poly(L-lysine) (PLL) polyionic complex 
micelle is based on a design originally developed by the Kataoka laboratory (Harada 
1995, Harada 1998, Kakizawa 1999).  The micelles self-assemble via electrostatic 
interactions between the polylysine block and the protein or nucleic acid, forming the 
core of the micelle.  The PLL block is modified with pyridyldithio groups to allow for 
cross-linking by a dithiol molecule.  The disulfide cross-linking is designed to be cleaved 
in the intracellular reducing environment, enabling release of the biotherapeutics.  An 
important development by the Murthy laboratory was the use of a Michael addition 
reaction to attach the pyridyldithio groups to the poly(Lys) chain, thereby retaining the 
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positive charge on the secondary amine.  Micelle formulations were prepared using 
various proteins and nucleic acids.  The micelles were initially developed for vaccine 
applications, in which a model protein antigen (ovalbumin) was encapsulated alone or 
with DNA- or RNA-based immunostimulatory agents.  Another application was later 
pursued, enzyme therapy, in which the model enzyme catalase was encapsulated.  The 
encapsulation of proteins, DNA, and RNA was confirmed by gel electrophoresis and 
filtration methods.  The size and morphology of the micelles was confirmed by dynamic 
light scattering and atomic force microscopy.  The efficacy of micelle-based vaccine 
formulations was tested in Specific Aim 3. 
 
Specific Aim 2.  Develop a pH-sensitive biodegradable polymer for fabricating 
microparticles encapsulating proteins/DNA/RNA and hydrophobic small molecules, as a 





















Figure 1.1  Cross-linked micelle delivery system for proteins and nucleic acids. 
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Hypothesis 2:  Using the acetal exchange reaction, a ketal-containing polymer can be 
synthesized that will exhibit pH-sensitive degradation into biocompatible products and 
will thus provide a platform for intralysosomal delivery of proteins/DNA/RNA. 
A new polymerization method was developed, based on the acetal exchange 
reaction, which produced hydophobic, linear polymers containing pH-sensitive ketal 
linkages in the backbone (Figure 1.2).  This new polymer, termed a polyketal, has a 
combination of properties not found in existing drug delivery polymers, namely pH-
sensitivity, biodegradability, ease of synthesis, and non-acidic degradation products.  
Polyketals were used to fabricate pH-sensitive microparticles that are designed to release 
drugs or biotherapeutics in the acidic endosome of phagocytic cells.  Additionally, the 
technique of hydrophobic ion pairing was utilized to enhance the encapsulation of 
ovalbumin, DNA, and RNA in the polyketal microparticles via a single emulsion method.  
 
The chemical structure of the polyketals was characterized by gel permeation 
chromatography (GPC) and nuclear magnetic resonance (NMR) spectroscopy, and pH-
R O O *
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Figure 1.2.  Polyketal-based delivery system for proteins, nucleic acids, and 
hydrophobic molecules.
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sensitive degradation was demonstrated by NMR.  Encapsulation of ovalbumin, DNA, 
and RNA was measured using standard fluorescent labeling or fluorescent staining 
techniques.  Various polyketal microparticle-based vaccine formulations were evaluated 
for their efficacy in Specific Aim 3. 
 
Specific Aim 3:  Demonstrate the in vitro and in vivo efficacy of model vaccine 
formulations containing ovalbumin and immunostimulatory agents, using the cross-
linked micelle and polyketal microparticle delivery systems. 
Hypothesis 3:  Encapsulation of ovalbumin and Toll-like receptor (TLR) agonists in a 
micelle or polyketal microparticles can enhance the cross-priming of cytotoxic T 
lymphocytes. 
The efficacy of the two vaccine delivery systems (cross-linked micelles and 
polyketal nanoparticles) was evaluated using in vitro and in vivo methods.  The model 
vaccine formulations contained ovalbumin plus one or more immunostimulatory agents, 
including agonists for TLRs 3, 4, and 9.  In an in vitro cross-priming assay, murine 
splenic dendritic cells were treated with vaccine formulations and co-cultured with OT-1 
splenocytes for 4 days.  The expanded splenocytes were re-stimulated with ovalbumin 
peptide (SIINFEKL), and cross-priming was assayed by measuring the production of the 
cytokines interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and interleukin (IL)-2.  For 
the in vivo studies, mice were immunized with the model vaccine formulations and 
peripheral blood mononuclear cell (PBMC) samples were taken at later time points.  
Harvested cells were stimulated with SIINFEKL peptide and assayed for intracellular 
cytokine production. 
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1.3  Review of Relevant Literature 
Mechanism of inducing cellular immunity 
 Traditional vaccines for viral infections have largely been developed using 
empirical methods and typically consist of live attenuated or inactivated viruses or 
purified virus proteins adjuvanted with aluminum-based compounds.  Despite the 
decades of successful use, very little was known about vaccines’ mechanism of action 
until recent years.  Through the discovery of the Toll-like receptors (TLRs) and other 
receptors that recognize pathogen-associated molecular patterns (PAMPs), researchers 
have begun to elucidate the mechanisms by which pathogens (or vaccines derived form 
pathogens) induce adaptive immune responses (Akira 2001).  This process begins with 
the uptake of a vaccine or pathogen by an antigen-presenting cell (APC).  The APC 
processes the pathogen proteins by cleaving the proteins into peptide fragments and 
displaying the peptides on major histocompatibility (MHC) molecules on the cell surface.  
T lymphocytes with T cell receptors (TCRs) specific to the peptide antigen bind to the 
MHC-peptide complex, which constitutes the first signal in APC-T cell interaction.  A 
second signal comes in the form of costimulatory molecules, such as B7-1 (CD80) and 
B7-2 (CD86), which are also displayed on the APC cell surface and engage T cell 
ligands.   
 The presence of only these two signals can lead to tolerance, and thus a third 
signal is required to fully activate the APC and induce a robust T cell response.  This 
third signal consists of cytokines such as interleukin (IL-12) and type I interferons (IFN-α 
and IFN-β), which are induced by TLR activation (Mescher 2006).  IFN-α and IFN-β 
mediate an antiviral response through the production of viral replication inhibitors, the 
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recruitment of inflammatory cells, and the upregulation of MHC protein expression 
(Guidotti 2001).  The proinflammatory cytokine IL-12 provides a link between the innate 
and adaptive immune response, through the production of IFN-γ, which promotes 
recruitment and activation of inflammatory cells and upregulation of antigen processing 
and presentation.  IL-12 also promotes a T helper 1 (Th1) bias, which leads to expansion 
of cytotoxic T lymphocytes (CTL) to mount an attack against intracellular pathogens 
(Trinchieri 2003).  
 
Toll-like receptors (TLRs) as immunostimulatory adjuvants 
 The Toll-like receptors are a class of pathogen-recognition receptors within the 
innate immune system that detect the presence of bacteria and viruses in the extracellular 
space of endosomal compartments.  Engagement of TLRs leads to production of IFN-α 
and IL-12 through two distinct pathways.  All TLRs except TLR3 signal through a 
myeloid differentiation factor 88 (MyD88) pathway, whereas TLR3 and TLR4 signal 
through a MyD88-independent pathway.  TLR3 and TLR4 signal through an adaptor 
termed the Toll-IL-1 receptor (TIR) domain containing adaptor inducing IFN-β (TRIF), 
through an intermediate TRIF-related adaptor molecule (TRAM).  The MyD88 and TRIF 
pathways lead to the activation of nuclear factor (NF)-κB and IRF-3, which promote the 
expression of pro-inflammatory cytokines and chemokines (Pashine 2005). 
 Several of the TLRs are important in stimulating cellular immunity, by inducing a 
TH1 bias in the CD4+ T cell response.  For example, TLR4 is a cell surface receptor that 
recognizes lipopolysaccharide (LPS), a component of bacterial cell wall.  
Monophosphoryl lipid A (MPL) is a synthetic TLR4 agonist that is being developed for 
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hepatitis B and human papillomavirus vaccines and to treat non-small-cell lung cancer, 
among other applications (Kanzler 2007).  TLR9 recognizes unmethylated DNA 
containing “CpG” motifs, which is characteristic of bacterial DNA (Klinman 2004a, 
2004b, 2006).  CpG-DNA is administered in soluble form or conjugated to a protein 
antigen.  Clinical application under development include vaccines for hepatitis B, 
anthrax, influenza, HIV, and melanoma (Kanzler 2007).  Recently several groups have 
developed microparticles encapsulating CpG-DNA with protein antigens and have 
demonstrated enhancement of CD8+ T cell responses (Kwon 2005b, Heit 2007, Standley 
2007, Zhang 2007).  TLR7 is an endosomal receptor that recognizes single-stranded viral 
RNA (Heil 2004, Pashine 2005).  Synthetic TLR7 agonists such as Imiquimod have been 
developed which have more “drug-like” properties.  Imiquimod has been approved for 
treatment of basal cell carcinoma and papilloma-induced genital warts and is under 
clinical development for other applications (Kanzler 2007).   
 TLR3 is an endosomal receptor that recognizes double-stranded (ds)RNA, 
including the dsRNA analog poly(inosinic acid)-poly(cytidylic acid) (poly(I:C)) 
(Alexopoulou 2001).  Studies have shown that interaction of dsRNA with TLR3 depends 
on the acidification of the endosome (de Bouteiller 2005, Schulz 2005, Kumar 2005).  
Viral dsRNA and poly(I:C) induce maturation of dendritic cells (DCs), high IL-12 
expression, effective MHC-I antigen presentation, and strong T cell proliferation (Verdijk 
1999, Loré 2003, Schulz 2005).   Poly(I:C) has been investigated as a potential adjuvant 
for intranasal influenza vaccines, therapeutic treatment of cervical cancer, and treatment 
of herpes simplex virus type 2 infection (Ichinohe 2005, Cui 2006, Herbst-Kralovetz 
2006).  While TLR3 was the first receptor identified for dsRNA, the cytosolic receptor 
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melanoma differentiation associated gene 5 (Mda5) is also stimulated by dsRNA (Gitlin 
2005, Kato 2006). 
 The property of poly(I:C) as a pro-inflammatory agent makes it a potentially 
effective vaccine adjuvant; however, there may be concerns with the systemic 
inflammation resulting from high doses of soluble poly(I:C).  For example, one study 
reported that intraperitoneal (i.p.) injection of poly(I:C) in mice at doses of 2 to 12 mg/kg 
resulted in sickness behavior, reduced body weight, and fever (Cunningham 2007).  
Another study showed that i.p. injection of 3 mg/kg of poly(I:C) in rats resulted in 
reduced running wheel activity and increased expression of IFN-α in the central nervous 
system (Katafuchi 2003).  Similarly, i.p. injection of 5 mg/kg of poly(I:C) in mice was 
shown to reduce exercise capacity and increase levels of IFN-α and IFN-β in the 
bloodstream (Davis 1998).  These findings suggest that targeted delivery of poly(I:C) 
would be needed in order to reduce the adjuvant dosage and limit systemic effects. 
 
Co-delivery of antigen and adjuvants 
Recently, many studies have focused on the co-delivery of antigen and TLR 
agonists to enhance Th1 responses and cross-priming of CTLs.   For example, while 
CpG-DNA is often administered in soluble form, a few studies have demonstrated the 
advantages of co-delivery of CpG-DNA with antigen.  The Raz laboratory conjugated 
ovalbumin (a tumor model antigen) to CpG ssDNA (TLR9 ligand) and showed that the 
conjugate was more effective at suppressing an ovalbumin-expressing tumor than 
treatment with Ova antigen or CpG DNA alone (Cho 2000).  Tafaghodi et al. (2006) 
encapsulated tetanus toxoid (TT) with CpG-ODN in alginate microspheres for a vaccine 
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administered intranasally to rabbits, and showed improved IgA response in nasal lavages 
with TT/CpG versus TT microparticles or corresponding non-particle controls.  Also, the 
Fréchet group has demonstrated that hydrogel nanoparticles containing ovalbumin and 
CpG-DNA stimulate DCs to produce higher levels of IL-12 and induce stronger CD8+ T 
cell responses compared to Ova nanoparticle or free CpG DNA controls (Kwon 2005b, 
Standley 2007).   TLR4 ligands have also been employed as adjuvants.  For example, the 
Samuel laboratory has shown an effective in vivo T cell response in mice by co-
encapsulating ovalbumin with MPL (a TRL4 ligand) in PLGA nanoparticles (Hamdy 
2007).  The common finding in these studies is that injection of conjugated or co-
encapsulated antigen/TLR ligand generates a stronger immune response than co-injection 
of separate antigen and TLR ligand. 
 
Other protein/DNA delivery systems 
Various other delivery systems have been developed to deliver proteins and 
nucleic acids for vaccine applications.  Uto et al. encapsulated ovalbumin in poly(γ-
glutamic acid) (γ-PGA) nanoparticles and showed increased cytokine production, 
upregulation of costimulatory molecules, and enhanced antigen-specific B and T cell 
stimulation with Ova-nanoparticles.  Also, listerolysin (LLO) peptide immobilized on the 
γ-PGA NPs protected mice from infection with Listeria monocytogenes bacteria (Uto 
2007).  A DNA vaccine formulation was prepared by complexing polyethylene amine 
(PEI) with plasmid (p)DNA and reacting it with PEG-NHS to form a PEGylated 
polyplex, which was encapsulated in PLGA microparticles.  Oral delivery to rats resulted 
in plasmid DNA transgene expression of β-galactosidase in the spleen (Howard 2004).  
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Another DNA delivery vehicle consists of pDNA complexed with thiolated multi-arm 
PEG, crosslinked to form 300-800 nm size particles; the PEG nanogels exhibited 
glutathione-sensitive release of pDNA (Mok 2006).  Mohamed et al. fabricated hollow 
dimpled PLGA microcapsules for pulmonary vaccine delivery.  The low density 8 µm 
particles have a 3-4 µm aerodynamic diameter, which is suitable for delivery to the 
bronchus associated lymphoid tissue (BALT) and lung periphery (Mohamed 2006). 
 
Polyionic Crosslinked (PIC) Micelles for Delivery of Charged Molecules 
 The formation of polyionic complex (PIC) micelles was first reported by Harada 
and Kataoka (1995), where stable complexes were produced from a stoichiometric 
mixture of poly(ethylene glycol)(PEG)-poly(Lys) and PEG-poly(Asp) in aqueous buffer.  
The complexes were formed through the electrostatic interactions between the poly(Lys) 
and poly(Asp) chains, with the PEG chains forming the corona, or shell, of the micelle.  
This concept was further developed through the addition of disulfide cross-linking to 
stabilize PIC micelles.  Is this design, the micelles were composed of PEG-poly(Lys) and 
PEG-poly(Asp), where a portion of the lysine residues were modified through a reaction 
with SPDP and reduced to give free thiols (Kakizawa 1999).  After complexation, the 
thiols were oxidized to form disulfide cross-links, which provide micelle stability even at 
high salt concentrations.  The disulfide cross-linking was intended for intracellular 
delivery of charged biomolecules, based on evidence that a stronger reductive 
environment exists intracellularly (Huang 1998).  Cross-linked micelles were also formed 
with thiolated PEG-poly(Lys) and antisense DNA, and were shown to be stable against a 
competing polyelectrolyte, poly(vinyl sulfate) (PVS), and yet release the DNA upon 
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treatment with PVS and glutathione (Kakizawa 2001, Miyata 2005).  The PIC micelles 
have also been used for applications in delivering plasmid DNA and siRNA (Katayose 
1997, Miyata 2005, Nishiyama 2006a, Nishiyama 2006b). 
 The Kataoka group also demonstrated that PIC micelles could be formed with 
PEG-poly(Asp) and proteins such as trypsin and lysozyme (Harada 1998, Harada 1999, 
Harada 2001, Jaturanpinyo 2004).  The lysozyme micelles were shown to have greater 
enzyme activity than free lysozyme, which was attributed to attraction of the substrate by 
the PEG corona, which resulted in a decrease in the observed Michaelis constant (Harada 
2001).  Poly(Asp) micelles with trypsin were prepared using glutaraldehyde to cross-link 
the trypsin molecules within the core.  The micelles were shown to have less trypsin 
degradation (more retention of enzyme activity) than free trypsin, supposedly due to 
immobilization of trypsin in the core, which prevented autolysis of the enzyme. 
(Jaturanpinyo 2004) 
 
pH-Sensitive Vaccine Delivery Systems 
The property of pH-sensitivity has been pursued in many drug delivery vehicles 
as a means of achieving intracellular release through degradation of the polymer in the 
acidic lysosomal compartment.  The Frechet laboratory has developed polyacrylamide 
nanoparticles that contain acid-cleavable cross-linkers (Murthy 2003b, Standley 2004).  
The nanoparticles are prepared by inverse microemulsion polymerization of acrylamide 
monomers with a benzyl acetal bisacrylamide monomer.  In one system, a 
trimethylammonium monomer were used to create cationic nanoparticles encapsulating 
ovalbumin, with CpG-DNA or IL-10 antisense DNA complexed to the surface of the 
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particles.  The ovalbumin/CpG-DNA nanoparticles were shown to enhance IL-12 
production in bone marrow-derived dendritic cells (BMDCs) versus ovalbumin 
nanoparticles or free CpG-DNA.  Also, IL-10 antisense ODN-coated ovalbumin 
nanoparticles were shown to have a moderate reduction in IL-10 production as compared 
to free IL-10 antisense ODN. (Kwon 2005b)  In another variation on the hydrogel design, 
CpG-DNA was derivatized with methacrylamide to be incorporated into the acetal 
crosslinked polyacrylamide nanoparticles.  Nanoparticles containing ovalbumin and 
CpG-DNA enhanced stimulation of IL-12 and surface activation markers in BMDCs as 
compared to ovalbumin particles, and also induced strong ovalbumin-specific cytotoxic T 
cell responses in mice. (Standley 2007) 
 
Hydrophobic Ion Pairing 
 The technique of hydrophobic ion paring has been developed by several research 
groups as means of altering the solubility of proteins and nucleic acids, through the 
stoichiometric pairing with oppositely charged surfactants (Hegg 1979, Powers 1993, 
Bromberg 1994, Meyer 1998, Patel 2004, Dai 2007).  Various applications of ion pairing 
have been considered, such as making an enzyme available to a substrate that is soluble 
in a nonpolar solvent.  Another application is in the encapsulation of charged molecules 
in polymeric microparticles.  One group has utilized a microparticle fabrication method, 
precipitation with compressed antisolvent (PCA), which requires the drug molecules to 
be soluble in a nonpolar solvent (Falk 1997).  They have demonstrated that plasmid DNA 
can be ion paired with DOTAP via a Bligh-Dyer extraction method, producing a 
DNA:DOTAP complex that is soluble in dichloromethane (DCM), and have shown high 
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encapsulation efficiencies (>70%) in poly(lactic acid) microspheres. (Patel 2004)  It has 
also been shown that the anti-cancer drug cisplatin can be ion-paired with docusate 
sodium (aerosol OT, or AOT) to produce a compound with greater cytotoxicity toward 
cancer cells in vitro.  This effect was attributed to the greater hydrophobicity and 
consequent increase in cell permeability of the ion-paired cisplatin. (Feng 2004). 
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CHAPTER 2 
DEVELOPMENT OF CROSS-LINKED  
BLOCK COPOLYMER MICELLES 
 
2.1 Introduction 
In this chapter we discuss Specific Aim 1, which was to develop a cross-linked 
micelle delivery system for efficient encapsulation of proteins and nucleic acids.  Polyion 
complex (PIC) micelles had originally been developed by the Kataoka laboratory and 
were based on self-assembly of a poly(ethylene glycol)(PEG)-poly(Lys) or PEG-
poly(Asp) block copolymer with charged molecules such as DNA or proteins.  The core 
of the micelle is formed via electrostatic interactions between the polylysine and DNA, or 
between the poly(Asp) and positively charged proteins such as lysozyme or trypsin, while 
the PEG chain occupies the shell, or corona, of the micelle. (Harada 1995, Kakizawa 
1999, Kakizawa 2001).  Various cross-linking schemes have been developed, such as 
disulfide linkages and aldehyde-amine reactions.  The cross-linking provides for transport 
stability in serum or extracellular fluid, where the presence of competing charged 
molecules would cause disruption of the electrostatic interactions.  Figure 2.1 shows a 
schematic of the PIC micelle self-assembly and cross-linking. 
The aldehyde cross-linking of trypsin within the PIC micelle, as reviewed in 
Chapter 1, does not however generate a stimulus-responsive release mechanism for 
intracellular delivery.  The disulfide cross-linking method used with thiolated PEG-
poly(Lys), on the other hand, was effective at generating stable complexes with DNA and 
offers a means of intracellular release through cleavage by reducing agents such as 
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glutathione (Huang 1998).  However, it may not securely encapsulate proteins, which 
generally have fewer charged groups available for electrostatic complexation.  
Furthermore, in the Kataoka design, the pyridyldithio cross-linking moiety was attached 
by reacting the PLL backbone with SPDP.  The reaction of the lysine amine with the 
succinimidyl group produces an amide bond, which means one positive charge is lost for 
each cross-linking group added.  Because the positive charges are needed for 
complexation, an improvement would be to use a reaction that would attach pyridyldithio 
groups without losing positive charges on the poly(Lys) chain. 
 
We hypothesized that efficient encapsulation and retention of proteins, DNA, and 
RNA could be achieved by optimizing the parameters governing the self-assembly 
(electrostatic complexation) and cross-linking of a PIC micelle delivery system.  As a 
starting point for our PIC micelle design, we chose PEG-poly(Lys) as the block 
copolymer, which had previously been used to complex DNA.  The initial goal of this 




project was to deliver ovalbumin and CpG-DNA for a model vaccine.  Therefore, PEG-
poly(Lys) would be suitable to complex with CpG-DNA and ovalbumin, which has an 
isoelctric point of pH 5 and carries a net negative charge.  In order to retain the positive 
charges on poly(Lys), we developed a new method of attaching the pyridyldithio group 
via a Michael addition, which generates a secondary amine.  Thus, we can maximize the 
number of disulfide groups and positively charged amines, to optimize the complexation 
and cross-linking.  An additional improvement was the conjugation of pyridyldithio 
groups to ovalbumin to covalently tether the protein to the PEG-poly(Lys) in the core of 
the micelle. 
For vaccine applications, we developed micelles containing peptide- and protein-
based antigens.  These vaccine formulations are designed to deliver antigen and 
immunostimulatory adjuvants to phagocytic antigen-presenting cells (APCs) to induce 
activation of the APCs and cross-priming of cytotoxic T lymphocytes (CTLs).  The 
original micelle developed in the Murthy laboratory was the peptide-crosslinked micelle 
(PCM), in work led by Jihua Hao (Hao 2006).  In the PCMs, the antigenic peptide 
SIINFEKL was modified with two cysteine residues and served as the cross-linking 
agent, while immunostimulatory CpG-DNA was the polyionic complexing agent in the 
core of the micelle.  The PCMs were shown to be stable in a solution of poly(vinyl 
sulfate) (PVS), which is intended to represent the conditions in serum or extracellular 
fluid, where the presence of competing amphiphilic molecules would cause disruption of 
the electrostatic interactions.  It was also shown that the disulfide cross-linking bonds can 
be cleaved by reducing agents such as glutathione (GSH), which is found in higher 
intracellular concentrations versus in the bloodstream (Huang 1998).  Additionally, the 
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PCMs enhanced the uptake of FITC-labeled peptide antigen by dendritic cells (Hao 
2006). 
In our subsequent work with protein-loaded micelles, we encapsulated the whole 
protein antigen ovalbumin along with immunostimulatory nucleic acids (CpG-DNA and 
poly(I:C)).  We demonstrated retention of CpG-DNA and poly(I:C) by agarose gel and 
retention of ovalbumin by SDS-PAGE.  We also showed that covalent tethering of 
ovalbumin via a pyridyldithio group resulted in better protein retention than untethered 
ovalbumin.  The efficacy of the ovalbumin-based model vaccine formulations was tested 
in vitro using primary murine dendritic cells and OT-1 splenocytes, and in vivo in mice, 
as described in Chapter 4. 
  
2.2 Experimental Methods 
Synthesis of PEG-poly(lysine-dithiopyridyl) (PEG-PLTP) copolymer.  
Synthesis of PEG-Polylysine Block Copolymer. 
The block copolymer backbone, consisting of a 5000 molecular weight PEG chain 
and approximately 10 to 20 lysine repeats, was synthesized by the methods developed by 
the Kataoka laboratories (Harada 1995, Kakizawa 1999).  Briefly, the N-
carboxyanhydride (NCA) of ε-benzyloxycarbonyl-L-lysine (Lys(Z)-NCA) was generated 
by reacting Lys(Z)-OH (10 g, 35.7 mmol) with triphosgene (5.3 g, 17.8 mmol) for 4 
hours at 50°C in dry THF.  The product was recrystallized three times in cold hexanes, 
with a 72% yield.  The poly(ethylene glycol)-block-poly(L-lysine(Z)) (PEG-PLL(Z)) 
copolymer was synthesized via a ring-opening polymerization of α-methoxy-ω-amino-
PEG (1.0 g, 0.2 mmol) with Lys(Z)-NCA (3.66 g, 12 mmol) for 20 hours at 40°C in 
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anhydrous DMF.  The product was precipitated in cold ethyl ether, vacuum filtered, and 
vacuum dried to yield 1.5 g of PEG-PLL(Z) block copolymer.  From the 1H NMR 
spectrum, the degree of polymerization (d.p.) was calculated to be 30.8.  Deprotection of 
the ε-benzyloxycarbonyl group was carried out by mixing PEG-PLL(Z) with 
trifluoroacetic acid, then a mixture of anisole and methanesulfonic acid, followed by 
ether/water extraction.  The aqueous phase was dialyzed against a 1000 molecular weight 
cut-off membrane, and lyophilized to yield 543 mg of PEG-PLL.  After deprotection, the 
d.p. was calculated to be 13.7 based on the 1H NMR spectrum.  The change in d.p. during 
the deprotection step was attributed to low molecular weight polylysine chains that were 
initiated by water molecules in the ring-opening polymerization reaction, and were 
subsequently removed during dialysis.  
 
Synthesis of Side Chain Monomer Pyridyldithio-Ethylacrylate 
Synthesis of pyridyldithioethylacrylate is described by Hao and Murthy (2006).  
Briefly, mercaptoethanol (0.886 g, 11.36 mmol) was reacted with 2,2-dithiodipyridine (5 
g, 22.7 mmol) and acetic acid (1.36 g, 22.7 mmol) in 15 mL of methanol for 1 hour at 
room temperature.  The 2-(2-pyridinyldithio)-ethanol product was purified by silica gel 
chromatography with 79.5% yield.  Next, 2-(2-pyridinyldithio)-ethanol (1.6 g, 8.56 
mmol) was dissolved in 16 mL of dichloromethane (DCM) with  triethylamine (1.297 g, 
12.84 mmol).  Acryloyl chloride (1.156 g, 12.84 mmol) was added in a dropwise manner 
to initiate the reaction.  After 1 hour, the product was purified by DCM/brine extraction 
(2 times), dried with sodium sulfate, and purified by silica gel chromatography, for a 45% 
yield of pyridyldithioethylacrylate (PDTEA). 
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Synthesis of Final Copolymer PEG-PLTP 
The pyridyldithioethylacrylate (PDTEA) side chain monomer was conjugated to 
the PEG-PLL backbone via a Michael addition reaction, which retains the positive charge 
on the lysine amine.  Briefly, PEG-PLTP (250 mg, 36.8 µmol) was dissolved in 6 mL of 
DMF, and PDTEA (133 mg, 552 µmol) was added with an additional 4 mL of DMF.  
Triethylamine (154 µL, 1.104 mmol) was added, and the reaction was run at 30°C 
overnight.  The reaction mixture was precipitated in 500 mL of cold ethyl ether, vacuum 
filtered, and vaccum dried to yield 179 mg of polymer.  The final polymer is termed 
poly(ethylene glycol)-block-poly(L-lysine-N-pyridyldithioethylethanoate) (PEG-PLTP) 
(Figure 2.2).  
Encapsulation of proteins, and nucleic acids in cross-linked copolymer micelles. 
The block copolymer PEG-PLTP was used to prepare polyionic complex micelles 
containing proteins and nucleic acids, including ovalbumin, catalase, CpG-DNA, and 
poly(I:C) (Figure 2.3).  The micelles were prepared by first combining solutions of FITC-
labeled ovalbumin, CpG-DNA, and/or poly(I:C), and vortexing to ensure thorough 









Figure 2.2.  PEG-poly(lysine-dithiopyridyl) (PEG-PLTP) block copolymer. 
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PLTP) copolymer was added to form the micelles.  Alternatively, PEG-PLTP was mixed 
with either FITC-labeled ovalbumin or FITC-labeled catalase.  The mixtures were left to 
stand at room temperature for 30 to 60 minutes to allow self-assembly of the micelles.  
Next, 3,6-dioxa-1,8-octanedithiol (DOODT) was added in a step-wise manner to 
crosslink the dithiopyridyl side chains through a disulfide exchange reaction.  The 
micelles were allowed to stand for 20 minutes following each addition of DOODT to 
complete the disulfide exchange. 
 
The step-wise cross-linking method was developed to ensure that the cross-
linking efficiency was as close as possible to 100%.  The amount of cross-linker thiols 
must be equimolar to the calibrated dithiopyridyl content of the PEG-PLTP polymer; if 
the amount of cross-linker is too high or too low, there will potentially be less than 100% 
cross-linking.  In a typical four-stage cross-linking, we add 70% of the stoichiometric 
amount of dithiol, followed by 15%, 10%, and 10%, at 20 minute intervals.  This method 
is preferred to simply adding an excess of DOODT, because that would result in some 
DOODT molecules reacting with a dithiopyridyl only at one end and not generating a 




















cross-link.  The stepwise method ensures that the cross-linking will be between 95-100%, 
assuming a +/-5% inaccuracy in the DOODT stoichiometry. 
The dithiopyridyl content of the PEG-PLTP solution was calibrated prior to 
micelle preparation, by reacting the polymer with dithiothreitol (DTT) and measuring the 
production of thiopyridone by the increase in absorbance at 342 nm.  In a similar manner, 
the micelle cross-linking can be monitored by reacting a small sample with DTT to 
determine if all of the dithiopyridyl groups have been converted. 
 
Covalent linkage of protein within micelle. 
While the Ova/CpG/poly(I:C) micelles showed high encapsulation and retention 
of the nucleic acids in agarose gels, it was found that the FITC-Ova was not completely 
retained when the micelles were subjected to SDS-PAGE (data not shown).  Thus, we 
modified the protein-based micelle by first reacting the ovalbumin with Sulfo-LC-SPDP, 
a commercially available reagent based on succinimidyl-pyridyl-dithio-proprionate 
(SPDP) (Pierce).  Briefly, a 6.0 mg/mL solution of ovalbumin (15 mg, 0.34 µmol) was 
reacted with Sulfo-LC-SPDP (2.15 mg, 4.08 µmol) and purified by PD-10 column.  This 
gave the Ova approximately 5 or 6 pyridyldithio groups per protein molecule, so that the 
Ova was covalently tethered to the PEG-PLL-dithiopyridyl polymer during the cross-




Characterization of Protein-Loaded Micelles 
Micelles Containing FITC-Ovalbumin, CpG-DNA, and Poly(I:C) 
Micelle-based vaccine formulations were prepared with concentrations of 10 mg/mL 
PEG-poly(L-lysine-dithiopyridyl), 0.5 mg/mL FITC-Ova, 1 mg/mL CpG ssDNA, and/or 
1 mg/mL poly(I:C).  An agarose gel stained with ethidium bromide shows that CpG-
DNA and Poly(I:C) are retained in the micelles (lanes 6, 7, and 8) (Figure 2.4).  FITC-
ovalbumin is retained in the FITC-Ova (lane 5) and FITC-Ova/poly(I:C) (lane 7) 
micelles, but is retained to a lesser extent in the FITC-Ova/CpG-DNA (lane 6) and FITC-
Ova/CpG-DNA/poly(I:C) (lane 8) micelles. 
 
 
Figure 2.4.  Agarose gel of cross-linked copolymer micelles with ovalbumin, CpG 
DNA, and poly(I:C) (9-25-05 batch).  Lanes: (1) free Ova, (2) free Ova/CpG, (3) free 
Ova/poly(I:C), (4) free Ova/CpG/poly(I:C), (5) micelle with Ova, (6) micelle with 
Ova/CpG, (7) micelle with Ova/Poly(I:C), (8) micelle with Ova/CpG/Poly(I:C). 
   1    2  3  4  5   6   7   8 
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Micelles Containing SPDP-FITC-Ovalbumin and CpG-DNA 
 The micelles made with Sulfo-LC-SPDP-modified FITC-Ova showed virtually 
100% retention of the Ova as determined by SDS-PAGE (Figure 2.5), as well as a 
significant degree of CpG DNA retention in agarose gel electrophoresis (Figure 2.6).  
The size and shape of the micelles were characterized by dynamic light scattering (DLS) 
(Figure 2.7) and atomic force microscopy (AFM) (Figure 2.8).  The micelles had an 
effective diameter of 130 nm, with clusters in the size distribution at 45 nm and 190 nm.  
AFM images show a spherical shape, and measurement of the half-peak widths ranged 








Figure 2.5.  SDS-PAGE (4-20%) of SPDP-Ova/CpG micelles, prepared with 0.5 















Figure 2.6.  Agarose gel of SPDP-Ova/CpG micelles, prepared with 0.5 mg/mL 
FITC-Ova-SPDP, 0.5 mg/mL CpG DNA, and 10 mg/mL PEG-poly(Lys-Thio-
Pyridyl). 
Figure 2.7.  Characterization of SPDP-Ova/CpG micelles by dynamic light scattering 















Figure 2.8.  Characterization of SPDP-Ova/CpG micelles by atomic force 
microscopy (AFM); approximate diameter = 50 to 150 nm. (Courtesy of Catherine 




Courtesy of Catherine Santai (Hud lab, Ga. Tech)
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Micelles containing catalase 
 Cross-linked micelles were prepared with Sulfo-LC-SPDP-conjugated catalase, 
with 1:20 and 1:40 ratios of catalase to PEG-PLTP.  Both samples showed a high degree 















Figure 2.9.  SDS-PAGE (4-20%) of SPDP-FITC-Catalase micelles, prepared with 




The objective of this research was to develop an improved polyion complex (PIC) 
micelle delivery system for proteins and nucleic acids.  The PIC micelle concept had first 
been demonstrated by the Kataoka laboratory as stable, self-assembled complexes 
between PEG-poly(Lys) and PEG-poly(Asp).  They later developed the PIC micelle as a 
delivery system for charged molecules, e.g., by complexing PEG-poly(Lys) with DNA 
and by complexing PEG-poly(Asp) with positively charged proteins such as trypsin and 
lysozyme.  Cross-linking schemes based on disulfide exchange reactions or aldehyde-
amine reactions were used to provide stability of the micelles against competing 
electrolytes or under dilute conditions.  In this project, we have focused on improving the 
chemistry involved in the cross-linking schemes, to generate a PIC micelle capable of 
efficient encapsulation and retention of a protein and/or nucleic acid.  In the context of 
developing a protein subunit vaccine, the cargo molecules were ovalbumin, CpG-DNA, 
and poly(I:C).  A secondary application was to deliver a therapeutic enzyme, for which 
we chose catalase as a candidate enzyme because of its applicability to treating 
inflammatory conditions (a focus area in the Murthy laboratory). 
 We used the PEG-poly(Lys) block copolymer as our platform for developing an 
improved micelle design.  The first modification was to use a Michael addition reaction 
to attach the pyridyldithio (PDT) cross-linking monomer to the PEG-poly(Lys) backbone.  
The Michael addition reaction was shown to proceed nearly quantitatively in DMF, 
resulting in a high number of PDT groups and retaining the positively charged amines.  A 
second change was to use a dithiol molecule to cross-link the PDT groups directly, in 
contrast to the reported method of reducing the PDT groups and allowing open air 
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oxidation to proceed over 3 days.  The direct cross-linking of PDT has the advantages of 
being more rapid and is easily monitored by the 342 nm absorbance of thiopyridone. 
 While this design was capable of a moderate degree of protein retention, an 
additional modification was introduced to covalently tether the protein in the core of the 
micelle, by conjugating multiple SPDP molecules to each protein molecule.  This method 
was shown to improve the retention of ovalbumin in SDS-PAGE assays.  It would be 
especially useful for proteins having a low charge density or neutral isoelectric point, in 
which case the electrostatic complexation and poly(Lys) core cross-linking would be 
insufficient to retain a globular protein.  Based on agarose gel assays, however, the 
covalent tethering does not appear to be as necessary for oligo- and polynucleotides, 
which are more linear and have a higher charge density than proteins, and thus form 
strong complexes with the poly(Lys) chain. 
 In summary, these improvements have resulted in a cross-linked micelle design 
that has efficient encapsulation and retention of ovalbumin, CpG-DNA, and poly(I:C), as 
well as the enzyme catalase.  The PEG-PLTP block copolymer is generated through a 
six-step convergent synthesis, using standard reaction mechanisms and commercially 
available reagents.  PEG-PLTP is stored in dry form and is reconstituted prior to micelle 
formation.  Preparation of cross-linked micelles requires about 3 to 4 hours and can be 
done under sterile conditions.  Furthermore, the micelles have the advantage that small 
scale batches can be efficiently prepared.  The developments reported here demonstrate 
that the cross-linked micelle is a promising delivery system for protein and nucleic acid 
therapeutics, with potential applications in vaccines or enzyme-based therapy. 
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CHAPTER 3 




 The overall objective of Specific Aim 2 was to develop a pH-sensitive 
biodegradable polymer which could be used to fabricate micro- or nano-sized particles 
for intracellular delivery of biotherapeutics and organic drugs.  Various polymers have 
been employed in making colloid nanoparticles, with poly(lactic-glycolic acid) (PLGA) 
being the most commonly used due to its excellent biocompatibility profile and 
commercial availability.  However, there are concerns over the highly acidic 
microclimate within degrading PLGA particles that may complicate the use of PLGA in 
delivering functional proteins and nucleic acids (Fu 2000).  Furthermore, numerous 
medical applications, such as targeting the acidic environment of lysosomes and tumors, 
require drug delivery systems that undergo rapid, pH-sensitive degradation.  Several pH-
responsive delivery systems have been reported for delivery of proteins and DNA 
(Murthy 2003b, Kwon 2005a, Kwon 2005b, Standley 2007).  These systems are ketal-
crosslinked hydrogels generated by free-radical polymerization and thus contain non-
degradable carbon backbone polymer chains.  Another family of pH-sensitive polymers, 
the poly(ortho ester)s, have lengthy synthetic routes and generate acidic degradation 
products (Wang 2004).  Therefore, there is a need for new materials for intracellular 
delivery of proteins and nucleic acids, that have the necessary combination of properties, 
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namely pH-sensitivity, biodegradability, ease of synthesis, and non-acidic degradation 
products. 
We hypothesized that by using the acetal exchange reaction, a ketal-containing 
polymer could be synthesized that would exhibit pH-sensitive degradation and thus 
provide a platform for intralysosomal delivery of proteins/DNA/RNA.  This new pH-
sensitive polymer would be synthesized in a one-step reaction and would have material 
properties needed for fabricating microparticles.  For example, the polymer would be 
sufficiently hydrophobic to be soluble in chloroform or dichloromethane, in order that the 
polymer could be used to fabricate nano- or microparticles using oil-in-water emulsion 
methods.  Another requirement was that the polymer would degrade into low molecular 
weight, water-soluble compounds, so that the degradation products could be excreted 
from the circulation.  Finally, it was desirable to develop a polymer which would not 
generate acidic degradation products, as with polyester-based materials such as PLGA.   
 
Development of the Acetal-Exchange Polymerization 
 In order to meet the requirements of pH-sensitivity and degradation into low 
molecular weight products, we decided to construct a polymer containing acid-labile 
acetal or ketal linkages in the polymer backbone.  Acetals and ketals are functional 
groups that are cleaved by acid-catalyzed hydrolysis and are commonly used in drug 
delivery polymers where intracellular, phagolysosomal release is desired.  We initially 
attempted to synthesize a ketal-containing molecule with an amine group on each end.  
The ketals are a subset of acetals in which neither substituent is a hydrogen.  We 
synthesized the precursor to the diamine ketal molecule, 2,2-di-(phthalimidoethoxy) 
 36
propane using the acetal exchange reaction (Sheppard 1989).  The diamine ketal 
molecule would be reacted with a molecule containing an acyl chloride group on either 
end.  The two molecules, designated A-A and B-B, would polymerize in a step-growth 
manner through the reaction of the amine with the acyl chloride, thus producing a linear 
polymer with a ketal and amide groups in the backbone.  
 A preliminary trial of the step-growth polymerization using 1,5-diaminopentane 
and terephthaloyl chloride resulted in a polyamide product which was not soluble in 
dichloromethane and chloroform and thus would not be suitable for the oil-in-water 
method of microparticle formation.  However, in our work with synthesizing the diamine 
ketal precursor molecule, we gained familiarity with the use of the acetal exchange 
reaction to generate ketal intermediates.  The acetal exchange reaction is an equilibrium 
reaction which can be driven forward by removal of one of the products (Lorette 1960).  
In the case where 2,2-dimethoxypropane is the starting ketal, the byproduct will be 
methanol, which can be removed by distillation.  We hypothesized that a ketal-containing 
polymer could be generated by directly reacting a diol (a molecule containing two 
alcohol groups) with 2,2-dimethoxypropane at a high temperature where the methanol 
byproduct would be distilled off.  This reaction would generate mixed ketal 
intermediates, which can combine with each other or with the starting materials in a step-
growth manner to form oligomer chains and eventually a polymer (Figure 3.1).  The 
acetal exchange method avoids the introduction of a amide bond and thus can produce a 
hydrophobic polymer.  The development of the acetal exchange polymerization led to the 
synthesis of various  ketal-containing polymers, termed “polyketals”, which could be 
used to fabricate microparticles via oil-in-water emulsion methods. 
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Development of Co-Polyketals Based on Cyclohexanedimethanol 
 We initially used the diol 1,4-benzenedimethanol to generate the prototype 
polyketal poly(1,4-phenylene-acetonedimethylene ketal) (PPADK) (Heffernan 2005).  
Because the hydrolysis of the ketal linkage produces a molecule of acetone and two 
alcohol groups, the degradation of PPADK were simply acetone and the original diol, 
1,4-benzenedimethanol.  One concern with 1,4-benzenedimethanol as a degradation 
product was that there was no data available on the compound’s toxicity.  An alternate 
diol compound was considered, namely 1,4-cyclohexanedimethanol (CDM), which has a 
known biocompatibility profile.  In work led by Stephen Yang of the Murthy laboratory, 
a solid polyketal (PCADK) was synthesized with CDM; however, its degradation rates 
were much slower than PPADK (Lee 2007).  Other polyketals were synthesized with 1,4-
butanediol, 1,5-pentanediol, and 1,8-octanediol; these polymers, however, were liquids at 
room temperature and thus were not suitable for microparticle formation.  Next, 
copolymers of CDM and the various short-chain diols were synthesized, resulting in solid 
co-polyketals with a range of degradation rates corresponding (inversely) to the 
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hydrophobicity of the monomers.  One of these is an 80:20 copolymer of CDM and 1,4-
pentanediol, termed PK3, which is suitable for microparticle fabrication and has 
relatively fast degradation kinetics (Yang 2008).  PK3 has a hydrolysis half-life on the 
order of 1 to 2 days and has material properties which are suitable for microparticle 
fabrication.  One significant property of PK3 is the biocompatibility of its degradation 
products.  As shown in Figure 3.2, the degradation products of PK3 have relatively high 
lethal dose values.  For the purpose of comparison, a typical in vivo application of the 
polyketal microparticles would require 50 mg/kg of polyketal; thus the amount of the 
degradation products would be much less than the reported LD50 values. 
 
Hydrophobic Ion Pairing  
 In this chapter we also describe the development of the hydrophobic ion pairing 
(HIP) technique for encapsulation of proteins and nucleic acids in polyketal 
microparticles.  We established the need for the ion pairing technique based on 
preliminary findings that proteins such as ovalbumin could not be encapsulated with high 
LD50 = 3200 mg/kg 
(Rat – oral) 
LD50 = 1600 mg/kg 
(Mouse – oral) 
LD50 = 6300 mg/kg 
(Rabbit – oral) 
LD50 = 20000 mg/kg 
(Rabbit - skin) 
LD50 = 5800 mg/kg 
(Rat – oral) 
LD50 = 7426 mg/kg 




Figure 3.2.  Toxicity of degradation products of co-polyketal PK3. (Sigma-
Aldrich MSDS) 
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efficiency using the water-oil-water double emulsion method.  These findings may have 
been due to insufficient polymer chain length and entanglement which allows escape of 
the protein from the inner aqueous phase to the outer aqueous phase.  The hydrophobic 
ion pairing technique has been reported in the literature for the extraction of water-
soluble biotherapeutics (DNA and proteins) into an organic solvent (Hegg 1979, Powers 
1993, Bromberg 1994, Meyer 1998, Patel 2004).  The basic procedure involves the 
pairing of a polar lipid or surfactant molecule with a (charged) DNA, RNA, or protein 
molecule, with an equimolar ratio of opposite charges (Figure 3.3).  This cancels the 
charges and produces a complex with a hydrophobic character.  The resulting 
hydrophobic complex can be co-dissolved with the polyketal in an organic solvent, or a 
mixture of solvents, enabling microparticles to be fabricated by the oil-in-water single 
emulsion method.  Because the hydrophobic complex partitions to the oil phase, this 
Figure 3.3.  Hydrophobic ion pairing of poly(I:C) to CTAB (top) and ovalbumin 





















































method has the potential to generate higher encapsulation efficiencies than the double 
emulsion method.  Several water-soluble compounds were encapsulated in polyketals 
using the HIP/single emulsion process, including ovalbumin, single-stranded oligo DNA, 
poly(I:C) (dsRNA), and siRNA.  
 
3.2  Experimental Methods 
Synthesis of Polyketals via the Acetal Exchange Reaction 
 As described in the Introduction, we developed a novel polymerization strategy 
based on the acetal exchange reaction, which generated a linear polymer with ketal 
groups in the backbone.  This synthesis uses a step-growth acetal exchange 
polymerization of a diol with 2,2-dimethoxypropane, yielding a polyketal (Figure 3.4).  
The reaction was based on a published protocol for the acetal-exchange reaction between 
N-(2-hydroxy ethyl) phthalimide and 2,2-dimethoxypropane (Sheppard 1989).  The first 
polyketal synthesized in the Murthy laboratory was poly(1,4-phenylene-
acetonedimethylene ketal) (PPADK) (Heffernan 2005).  Polyketals based on 1,4-
cyclohexanedimethanol as the primary diol were later synthesized (Lee 2007, Yang 
2008). 
 
Synthesis of poly(1,4-phenylene-acetonedimethylene ketal) (PPADK) 
 A schematic of the synthesis of PPADK is shown in Figure 3.4.  PPADK was 
synthesized in a 25 mL two-necked flask, connected to a short-path distilling head.  1,4-
Benzenedimethanol (1.0 g, 7.3 mmol) dissolved in 10 mL of warm ethyl acetate was 
added to 10 mL of distilled benzene kept at 100°C.  Re-crystallized p-toluenesulfonic 
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acid (5.5 mg, 0.029 mmol) dissolved in 550 µL of ethyl acetate was then added.  After 
allowing the ethyl acetate to distill off, distilled 2,2-dimethoxypropane (DMP, 900 µL, 
7.4 mmol) was added to initiate the reaction.  Five additional doses of DMP were added 
via a metering funnel, with each dose consisting of 2 mL of benzene plus 300 to 500 µL 
of 2,2-dimethoxypropane.   Each dose was added over a 30 to 40 min period with a 30 
min interval in between.  The total duration of the reaction was 7 h.  The reaction was 
stopped with the addition of 100 µL of triethylamine and was precipitated in cold 
hexanes.  The crude product was vacuum filtered, rinsed with ether and hexanes, and 
vacuum dried to yield 600 mg of white solid product (48% yield). (Heffernan 2005) 
 
Synthesis of Co-polyketal Based on 1,4-Cyclohexanedimethanol and 1,5-Pentanediol 
(PK3)   
 The co-polyketal PK3 was developed by Stephen Yang of the Murthy laboratory, 
using the acetal exchange polymerization (Yang 2008).  Two diols are reacted with 2,2-
dimethoxypropane to create a copolymer, as shown in Figure 3.5.  A typical synthesis of 
Figure 3.4.  Synthesis of the polyketal, poly(1,4,-phenylene-acetone dimethylene 
























PK3 is carried out in a 25 mL two-necked flask connected to a short-path distilling head.  
1,4-Cyclohexanedimethanol (5.0 g, 34.7 mmol) and 1,5-pentanediol (0.903 g, 8.67 mmol) 
were dissolved in 30 mL of distilled benzene at 100°C.  Re-crystallized p-toluenesulfonic 
acid (3.5 mg, 0.0197 mmol) dissolved in 3.5 mL of ethyl acetate was then added.  
Distilled 2,2-dimethoxypropane (DMP, 5.33 mL, 43.3 mmol) was added to initiate the 
reaction.  Additional doses of DMP (2.5 mL, 20.3 mmol) and benzene (5 mL) were 
subsequently added to the reaction every hour for 6 hours via a metering funnel at slow 
drip rate to compensate for DMP and benzene that had distilled off.  After 20 hours, the 
reaction was stopped with the addition of 2 mL of triethylamine.  The polymer was 
isolated by precipitation in cold hexanes (-20°C) followed by vacuum filtration.  
 
Characterization of Polyketals PPADK and PK3 
 The polyketals were characterized by gel permeation chromatography (GPC) and 
1H nuclear magnetic resonance (NMR) spectroscopy.  The GPC measurements were run 
in tetrahydrofuran (THF) using a Shodex KF-803 column with a Shimadzu SPD-10A 
Figure 3.5.  Synthesis of the co-polyketal PK3 via the acetal exchange 














UV-Visible detector.  Samples were analyzed against polystyrene standards (Mw = 1060; 
2970; 10,680) to calculate molecular weight, using Shimadzu software.  The 1H NMR 
spectra of the polyketals were run in CDCl3 using a Varian Mercury Vx 400 machine.  A 
small amount of triethylamine was added to the polyketal samples to prevent hydrolysis 
during the analysis. 
 
pH-Dependent Hydrolysis of PPADK 
The hydrolysis rates of PPADK were measured at lysosomal pH (5.0) and physiological 
pH (7.4).  To measure the hydrolysis rates, PPADK was ground into a fine powder and 
added to deuterated solutions at pH 7.4 (phosphate buffer), pH 5.0 (acetate buffer), and 
pH 1.0 (DCl) at a concentration of 10 mg/mL.  Dioxane was added to each sample as a 
reference molecule.  Next, the suspensions were stirred at 37°C and data points were 
taken at 3, 24, 48, and 72 hours.  Each suspension was centrifuged for 4 minutes at 
1800g, and a sample of the supernatant was analyzed by 1H NMR.  The NMR spectra 
contained peaks for 1,4-benzenedimethanol (7.24 and 4.47 ppm) and acetone (2.05 ppm).  
The average of the two 1,4-benzenedimethanol (BDM) peak integrals were used to 
determine the percentage of phenylene groups present as BDM; any phenylene groups 
present in the (water insoluble) polymer would not be present in the supernatant.  The 
eight dioxane protons served as a reference to normalize the BDM levels between the 
various samples.  The hydrolysis half-lives were determined by subtracting the percent 




Fabrication of polyketal nano- and microparticles using the oil-in-water emulsion 
method. 
Method 1:  Preparation of PPADK nanoparticles 
 Polyketal nanoparticles were made using a single oil-in-water emulsion/solvent 
evaporation method.  Typically, 50 mg of PPADK dissolved in 1 mL of CHCl3 was 
added to 5 mL of pH 9 buffer (10 mM NaHCO3) containing 0.2 to 1% poly(vinyl 
alcohol) (31–50 kDa) as the emulsifier.  The oil-water mixture was shaken briefly and 
then sonicated for 2 to 3 minutes at 40 watts using a Branson Sonifier 250 to form a fine 
oil-in-water emulsion.  The emulsion was stirred under nitrogen flow for at least 3 hours 
to evaporate the solvent and produce a nanoparticle suspension.  The nanoparticles were 
centrifuged at 4°C for 10 minutes at 5000g and washed with deionized water to prepare 
samples for scanning electron microscopy.  Particle sizes were analyzed by dynamic light 
scattering using a Brookhaven 90Plus particle sizer. (Heffernan 2005) 
 
Method 2:  Preparation of Polyketal Microparticles Containing Ova:CTAB and 
poly(I:C):CTAB Complexes 
 Microparticles were fabricated using an oil-in-water emulsion, solvent 
evaporation method.  The oil phase contained 50 mg of PK3 dissolved in 400 µL of 
chloroform, plus 0.8 mg of Ova:CTAB in 400 µL of 1:1 chlorform-DMSO and 0.9 mg of 
poly(I:C):CTAB in 150 µL of 4:1 chloroform-methanol.  Control batches included 
Ova:CTAB particles, poly(I:C):CTAB particles, or empty particles.  The total volume of 
the organic phase was made up to 1.2 mL with chloroform and homogenized in 15 mL of 
5% PVA solution at for 2 minutes 24000 rpm.  The resulting emulsion was poured into 
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85 mL of 1% PVA solution and stirred for 4 hours to evaporate the chloroform.  The 
PVA solutions were buffered with 8 mM sodium phosphate (pH 8) to prevent hydrolysis 
of the acid-sensitive polyketal.  The microparticles were collected by centrifugation at 
10000 g, washed once with OmniPur water, resuspended in 5 mL OmniPur water, then 
lyophilized overnight.  Particle yields were 25% to 70% of the starting polyketal mass.  
The size and morphology of the microparticles were characterized by dynamic light 
scattering (DLS) and scanning electron microscopy (SEM).  DLS samples were prepared 
by re-suspending the lyophilized particles in water and vortexing and bath sonicating for 
a few minutes.  The SEM samples were prepared either by spreading dry microparticles 
onto sticky carbon tape or by drying a drop of re-suspended particles on the metal SEM 
mounting stub. 
 
In vivo delivery of polyketal nanoparticles to murine macrophages. 
 In collaboration with Dr. Robert Pierce at the University of Rochester, we 
investigated the delivery of polyketal nanoparticles (PKNs) to liver macrophage cells.  
PPADK particles were prepared by Method 1 as described above, except that fluorescein 
was dissolved along with the polyketal in the chloroform phase. The attempted loading 
was 1% fluorescein by mass.  A volume of 200 µL of (10 mg/mL) fluorescein-containing 
PKNs was injected into the tail vein of mice.  The mice were sacrificed after 1 hour.  
Frozen sections of liver and spleen were fixed in 4% paraformaldehyde, stained with the 
macrophage marker F4/80, and analyzed by fluorescent microscopy and 
immunohistochemistry (IHC).   
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Hydrophobic Ion Pairing  
The hydrophobic ion pairing technique was used to convert various nucleic acid 
and protein molecules to hydrophobic complexes that could be dissolved in organic 
solvents or mixtures of solvents.  For oligonucleotides, such as 20-base single-stranded 
(ss)DNA or 21 base-pair short interfering (si)RNA, we used a water-dichloromethane 
(DCM)-methanol procedure with the surfactant 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP).  For ovalbumin, the water-DCM-methanol method resulted in 
aggregation, so a purely aqueous method was developed, using the surfactants DOTAP, 
docusate sodium, and cetyltrimethylammonium bromide (CTAB).  Similarly, poly(I:C) 
could not be ion-paired by the water-DCM-methanol method, so the aqueous method 
with CTAB was utilized. 
 
Hydrophobic Ion Pairing of Oligonucleotides (CpG-DNA and siRNA) by the Water-
Dichloromethane-Methanol Procedure 
 The oligonucleotides CpG-DNA and siRNA were each ion paired with 1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP).  This method was adapted from a 
reported procedure for ion pairing plasmid DNA for encapsulation in microparticles 
(Patel 2004).  In a typical procedure, a solution of DNA or RNA (0.8 mg) in 1 mL TE 
buffer was combined with a solution of DOTAP (1.9 mg) in 1 mL dichloromethane 
(DCM) and 2.1 mL of methanol.  This mixture created a Bligh & Dyer monophase, 
which was allowed to stand for 5 minutes.  Next, we added 1 mL DCM and 1 mL water 
to bring about phase separation, and the two-phase mixture was vortexed for 1 minute.  
The mixture was then centrifuged at 1200 g for 5 minutes at 20°C.  The organic phase 
 47
was immediately isolated using a syringe, and the nucleic acid content was analyzed by 
UV absorbance at 260 nm.  This process resulted in nearly 100% extraction of DNA or 
RNA into the organic phase; however, the actual yield (70 to 80%) was limited by the 
volume of the DCM phase that could be isolated.  Scaling down the process by one-half 
resulted in slightly lower percent yield due to losses in the isolation step. 
 
Hydrophobic Ion Pairing of Ovalbumin with CTAB 
 Ovalbumin was first converted to the stabilized form (S-ovalbumin) by heating a 
10 mg/mL ovalbumin solution to 55°C for 20 hours in 100 mM, pH 10 sodium phosphate 
buffer, followed by desalting in a PD-10 column.  The S-ovalbumin solution was diluted 
to 1 mg/mL in OmniPur water and adjusted to pH 11 by addition of NaOH.  Next, 10 mL 
(10 mg) of S-ovalbumin solution (4°C) was added to 364 µL of cetyltrimethylammonium 
bromide (CTAB) solution (3.64 mg), resulting in a precipitate which was collected by 
centrifugation at 20000g for 20 minutes at 5°C.  The lyophilized S-Ova:CTAB ion-pair 
complex was dissolved in 1:1 chloroform-DMSO, at an approximate concentration of 1 
to 2 mg/mL as determined by UV absorbance at 280 nm.  The ratio of CTAB cations to 
ovalbumin anions was 0.7:1. 
 
Hydrophobic Ion Pairing of Poly(I:C) to CTAB. 
Poly(I:C) was also ion-paired with CTAB using a similar protocol at a molar 
charge ratio (+/-) of 1.32 to 1.  Poly(I:C) was initially dissolved in IDTE pH 7.5 buffer at 
a concentration of 2.26 mg/mL, as determined by the UV absorbance at 260 nm (50 
µg/mL/A.U., per supplier’s literature).  The poly(I:C) solution was diluted to 0.1 mg/mL 
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in OmniPur nuclease-free water and kept at 4°C.  Next, 10 mL of poly(I:C) solution (1 
mg) was combined with 1 mL of CTAB solution (1.52 mg), resulting in a precipitate 
which was collected by centrifugation at 20000g for 20 minutes at 5°C.  The lyophilized 
poly(I:C):CTAB complex was dissolved in 4:1 chloroform-methanol at a concentration of 
6 mg/mL as determined by absorbance at 260 nm. 
 
Characterization of Protein and Nucleic Acid Loading in Polyketal Microparticles  
 For measuring the encapsulation levels of protein, DNA, or RNA, a sample of 
microparticles (approximately 5 mg) was first digested in 200 µL of 0.01 M HCl (with 
0.25% SDS) over a 5 to 10 minute period.  The sample was vortexed and bath sonicated 
as needed to ensure uniform digestion.  This resulted in a slightly hazy solution which 
was neutralized with 400 µL of 0.05 M pH 9.5 sodium bicarbonate buffer.  At this point, 
different methods were used to analyze loading, depending on the type of molecules 
being analyzed.   
 For ovalbumin, we used a fluorescamine assay in a 96-well plate, with 3 wells per 
particle digest sample.  Ovalbumin standard dilutions were prepared in the same 
neutralized solution containing HCl, SDS, and sodium bicarbonate.  The plate was read 
with a Bio-Tek plate reader using KC4 software.   
 To measure Poly(I:C) content, the samples and poly(I:C) standards were diluted 
in IDTE pH 7.5 buffer and stained with SYBR Green I or OliGreen nucleic acid dye.  
The samples were analyzed using a Shimadzu RF-5301PC spectrofluorophotometer with 
an excitation of 494 nm for SYBR Green I and 480 nm for OliGreen. 
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 For siRNA-loaded microparticles, the digest mixture was diluted in half and the 
absorbance peak at 260 nm was recorded using a Shimadzu UV-1700 spectrophotometer.  
The absorbance difference between a plain polyketal microparticle sample and the siRNA 
particle sample was multiplied by the reported extinction coefficient for siRNA to obtain 
the concentration of siRNA in the sample. 
 
MTS Cell Viability Assay 
 RAW264.7 macrophage cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% FBS and Pen/Strep/Fungizone per ATCC’s protocol.  Cells 
were seeded overnight in a 96-well plate at 15,000 cells/150 µL/well.  Empty polyketal 
microparticles and particles containing Ova, poly(I:C), or Ova+poly(I:C) were re-
suspended in complete medium with vortexing and bath sonication.  Microparticle 
suspensions and solutions of Ova, poly(I:C), and CTAB were diluted in complete 
medium, and 50 µL of each dilution was added to triplicate wells.  After 5 hours, Cell 
Titer 96 MTS reagent was added at 30 µL per well, and the cells were incubated.  After 1 
hour incubation, the difference in absorbance at 490 nm and 650 nm was recorded using a 
Bio-Tek Synergy™ HT plate reader with KC4 software.  Measurements were corrected 
for background (medium only) and expressed as cell viability relative to untreated cells. 
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3.3  Results 
Synthesis of Polyketals 
 Using the acetal exchange polymerization method developed in the Murthy 
laboratory, the prototype polyketal PPADK was synthesized and purified.  Following the 
precipitation and drying steps, 600 mg of white solid product was recovered (48% yield).  
Analysis of polyketal batches by GPC indicated weight-average molecular weights 
ranging from Mw = 2290 to 4000, with a polydispersity index of 1.4 to 1.6 (Figure 3.6).  
The corresponding degree of polymerization ranges from 12.9 to 22.5 repeating units.  
The 1H NMR spectrum (Figure 3.7) shows repeating unit peaks at 7.3 ppm (4b), 4.5 ppm 
(4c), and 1.5 ppm (6a).  The peaks at 2.5 ppm and 1.0 ppm are due to the triethylamine 
added to prevent ketal hydrolysis.  The NMR spectrum confirms that the repeating unit of 
PPADK contains a ketal group (‘6a’).  Together, the GPC and 1H NMR data provide 
evidence for the successful synthesis of PPADK.  (Heffernan 2005) 
Figure 3.6.  GPC trace of PPADK in THF (Shimadzu SCL-10A). (Heffernan 2005). 
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pH-dependent hydrolysis of PPADK 
The percent hydrolysis of PPADK is plotted over a 3-day time course at pH 1.0, 
pH 5.0, and pH 7.4 (Figure 3.8).  The calculated exponential decay half-lives for the 
hydrolysis of PPADK are 102 hours at pH 7.4 and 35 hours at pH 5.0.  The pH 1.0 
sample was completely hydrolyzed by the first time point of 3 hours and thus did not 
have a calculated half-life.  The PPADK hydrolysis data show a 3-fold rate increase from 
pH 7.4 to 5.0, which is significantly less than the 250-fold rate increase observed for a 
water-soluble ketal in going from pH 7.4 to 5.0 (Kwon 2005a) .  It is hypothesized that 
the lower pH sensitivity of PPADK is due to its water insolubility, which limits the 
diffusion of water and creates a rate-limiting step that is pH-independent. 












Release of Rhodamine B from polyketal microparticles 
 The release kinetics of Rhodamine B from PCADK microparticles at room 
temperature are shown in Figure 3.9.   The particles were made by single emulsion and 
their diameter was approximately 5 µm by SEM.  The amount of rhodamine B released 
was determined by measuring the fluorescence of the supernatant following 
centrifugation.  The calculated half-lives were 1 day at pH 1.0, 5 days at pH 4.5, and 

























In vivo delivery of polyketal nanoparticles to murine macrophages. 
 In collaboration with Dr. Robert Pierce at the University of Rochester, PPADK 
particles (effective diameter 256 nm by DLS) containing 1% (nominal) fluorescein by 
weight were administered intravenously to mice, and liver histology was examined 1 
hour post-injection.  Fluorescent microscopy of the liver sections indicates that the PKNs 
are abundantly present throughout the liver, residing mainly in the Kupffer cells (data not 
shown).  Anti-FITC IHC confirms the presence of fluorescein-PKNs within the 
cytoplasm of a Kupffer cell lining a liver sinusoid (Figure 3.10).  Control “empty” PKNs 
were also administered and show virtually none of the punctate fluorescence 
characteristic of the fluorescein-PKNs.  Occasional green autofluorescent globules were 


















Figure 3.9.  Release of rhodamine B from PCADK microparticles at room 
temperature. 
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shown).  These likely represent scavenged cell debris.  Similarly, the splenic 
macrophages contained FITC-PKNs (data not shown).  
 
Hydrophobic Ion Pairing of Proteins and Nucleic Acids 
We used the technique of hydrophobic ion pairing to convert several water-
soluble molecules – CpG-DNA, siRNA, ovalbumin and poly(I:C) –  into hydrophobic 
complexes that were soluble in organic solvents or mixtures of solvents.  The most 
efficient ion pairing was achieved with the oligonucleotides (CpG-DNA and siRNA) 
using the water-DCM-methanol procedure.  This method typically results in nearly 
complete extraction of the nucleic acid into the DCM phase, with the yield being limited 
by the amount of the DCM phase that could be isolated.  Typical yields were 70-80% 
based on UV absorbance measurements.   
Figure 3.10.  Release of fluorescein from PPADK nanoparticles.  
Dark red = anti-FITC staining; Blue = DAPI staining (nuclei). 
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Initial attempts to ion pair DOTAP to either poly(I:C) or ovalbumin were 
unsuccessful due to aggregation at the DCM-water interface. Thus, a purely aqueous 
method was developed, and we were successful in ion pairing ovalbumin to three 
different surfactants:  docusate sodium, DOTAP, and CTAB.  In the case of docusate 
sodium, which is negatively charged, the ovalbumin solution was adjusted to pH 4, 
whereas with DOTAP and CTAB the ovalbumin solution was adjusted to pH 11.  In all 
three cases, the resulting ion-pair complexes were soluble in a chloroform-DMSO 
mixture.  Because the objective of this study was to co-encapsulate ovalbumin and 
poly(I:C) in a microparticle, it was essential that the respective ion-paired complexes be 
compatible in solution.  It was observed that mixing of 1) an ovalbumin:docusate ion-pair 
dissolved in DMSO-chloroform and 2) a CpG-DNA:DOTAP ion-pair dissolved in DCM 
resulted in slight precipitation, from which it was concluded that ion-paired compounds 
would only be compatible in solution if the surfactants were of the same charge.  
Ovalbumin was thus ion-paired with one of the cationic lipids (CTAB), so that it would 
be compatible with poly(I:C) paired to a cationic lipid.  One issue with the ion-pairing of 
ovalbumin was the formation of aggregates that could not be dissolved in the organic 
solvents.  This resulted only about 10 to 15% of the ovalbumin being recovered after the 
lyophilization step.  Because aggregation is related to the stability of the protein, it was 
speculated that converting ovalbumin to the stabilized form, S-ovalbumin, would resulted 
in a higher yield when ion paired with CTAB.  CTAB was ion-paired with S-ovalbumin 
(at pH 11) with a yield of 15 to 20%.  The mass ratio was 0.364 to 1, which corresponds 
to a calculated charge ratio of 0.7 moles of CTAB cations to 1 mole of ovalbumin anions.  
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Characterization of Polyketal Microparticles  
 Microparticles were fabricated using the oil-in-water single emulsion methods 
described above.  Various small hydrophobic molecules, such as dyes or inhibitors, have 
been encapsulated by dissolving the molecule with the polyketal in the oil phase.  Initial 
attempts at using a double emulsion method to encapsulate water-soluble proteins, 
however, resulted in low encapsulation levels.  Thus, the hydrophobic ion pairing 
technique was used to form hydrophobic complexes of the proteins or nucleic acids with 
a surfactant.  The ion-paired complexes were efficiently incorporated into polyketal 
microparticles using a single emulsion method.  Figure 3.11 shows scanning electron 
microscope (SEM) images of representative polyketal microparticle batches.  Typical 






Cell toxicity of polyketal microparticles 
 An MTS cell viability assay was performed to measure cytotoxicity of polyketal 
microparticles containing ion-paired complexes.  RAW264.7 cells treated with 
microparticles containing Ova:CTAB and/or poly(I:C):CTAB complexes had 
approximately 50% cell viability at a concentration range of 0.05 to 0.25 mg/mL.  Plain 
polyketal microparticles were less toxic, with 70% cell viability at 1.25 mg/mL. (Figure 
3.12).  The corresponding concentrations of soluble ovalbumin and poly(I:C) were not 
toxic to RAW264.7 cells, however the ion-pairing surfactant CTAB showed significant 
toxicity at 0.8 µg/mL (Figure 3.13). 
Figure 3.11.  Scanning electron microscope images of microparticles fabricated 




Figure 3.12  MTS cell viability assay for polyketal microparticles containing 














































3.4  Discussion 
 In this study, the acetal exchange reaction has been shown to be an effective 
method of synthesizing a linear, hydrophobic polymer with pH-sensitive ketal linkages in 
the polymer backbone.  The acetal exchange polymerization uses the ketal as the joining 
group between 2,2-dimethoxypropane and a diol, and this method allows flexibility in the 
selection of the diol to achieve the desired combination of material properties and 
degradation products.  The incorporation of a pH-sensitive ketal linkage produces a 
polymer that is relatively stable at physiological pH (7.4) yet degrades more rapidly at 
acidic pH (5.0).  This property make polyketal microparticles useful as an intracellular 
delivery vehicle designed to undergo accelerated degradation and release in the acidic 
lysosomes of phagocytic cells.  Also, because the ketal linkage is contained in the 
backbone of the polymer, the polyketal will degrade into small molecules that are 
excretable.  This is a significant advantage over ketal cross-linked hydrogels that contain 
non-biodegradable carbon backbone polymers. 
Another important property of polyketals is that they do not have acidic 
degradation products.  This is in contrast to polyesters such as poly(lactic-co-glycolic 
acid) (PLGA), polyanhydrides, and poly(ortho ester)s.  One area of concern with 
polyester-based particles is that the acidic microenvironment within degrading particles 
can be deleterious to proteins or nucleic acids being delivered (Tamber 2005).  The pH 
within degrading PLGA microparticles has been estimated to reach levels as low as pH 2 
(Fu 2000, Shenderova 1999).  This has necessitated the inclusion of buffer salts in PLGA 
microparticle formulations or the modification of proteins (such as PEGylation) prior to 
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encapsulation, in order to protect acid-labile proteins from hydrolysis (van de Weert 
2000, Mok 2007).  A second area of concern is the release of acid within cells or into the 
surrounding tissue, which can lead to an inflammatory response.  The absence of acidic 
degradation products in polyketals is particularly important in delivering drugs or 
biotherapeutics to treat inflammatory diseases, because the generation of acid would itself 
cause inflammation.  This is also a consideration with pulmonary vaccines, where the 
release of acid from degrading microparticles might induce lung inflammation 
(Armstrong 1996, Segal 2007).  In other vaccine applications, this property allows the 
inflammatory response to be controlled by specific immunostimulatory adjuvants and 
localized to the targeted antigen-presenting cells, which offers a potential advantage over 
polyester-based biomaterials such as PLGA.   
 The cell toxicity of polyketal microparticles was measured with cultured RAW 
264.7 macrophages, using an MTS cell viability assay.  The toxicity was greater with the 
ion-paired ovalbumin and/or poly(I:C) formulations as compared to the plain polyketal 
particles.  The higher cytotoxicity of the ovalbumin/poly(I:C) particles is potentially due 
to the ion-pairing surfactant, CTAB, contained in the particles.  Based on the 
stoichiometry of the ion pairing procedures and the measured loading of ovalbumin and 
poly(I:C) in the microparticles, the combined Ova/poly(I:C) particles are estimated to 
have 22.5 µg/mg of CTAB.  Thus the particle dosage of 0.05 mg/mL, which exhibited 
approximately 50% toxicity, contained 1.13 µg/mL of CTAB.  The toxicity data for 
soluble CTAB showed a drop in cell viability at 0.8 µg/mL.  This suggests that a 
significant proportion of the ion-paired CTAB was released from the microparticles 
during the 5 hour incubation with cells.  This data for CTAB toxicity also falls within the 
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range reported for other cell lines treated with CTAB-containing liposomes, micellar 
solutions, cationic vesicles, and nanoparticles (Mirska 2005, Cortesi 1996, Kuo 2005, 
Delie 2001).  
In this study we have employed the technique of hydrophobic ion pairing to 
enable encapsulation of water-soluble components such as ovalbumin and poly(I:C) via a 
single emulsion, solvent evaporation method.  This method produced polyketal 
microparticles with loading levels in the range of 1% to 2% (wt/wt), which could not be 
achieved by the water-oil-water double emulsion method.  Hydrophobic ion pairing has 
been used by several groups to encapsulate nucleic acids and proteins in microparticles, 
with improved loading levels or release profiles (Choi 2006, Yoo 2004, Fu 2003, Patel 
2004, Delie 2001).  In the present study, we have achieved the first hydrophobic ion 
pairing of the double-stranded RNA analog poly(I:C) and the first co-encapsulation of 
ion-paired ovalbumin and poly(I:C) in a microparticle.  The methods developed in our 
study can potentially be used for other protein antigens and TLR ligands for vaccines, as 
well as delivery of nucleic acids such as plasmid DNA, mRNA, and siRNA. 
 In conclusion, we have developed a new family of pH-sensitive polymers, termed 
polyketals, which degrade into water-soluble, non-acidic products.  Polyketals are linear 
hydrophobic polymers that can be fabricated into microparticles using solvent 
evaporation methods.  Polyketals contain acid-labile ketal linkages in the backbone and 
are synthesized by a step-growth polymerization based on the acetal exchange reaction.  
Polyketals exhibit pH-sensitivity and thus the microparticles are designed to be stable at 
physiological pH yet release the vaccine components within the acidic phagolysosomes 
of dendritic cells.  Additionally, an adaptation of the hydrophobic ion-pairing technique 
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was used to improve the encapsulation efficiency of water soluble molecules.  Ovalbumin 
and the double-stranded RNA analog poly(I:C) were each ion-paired to the surfactant 
CTAB to produce hydrophobic complexes which were encapsulated in biodegradable 
polyketal microparticles.  The ion-paired polyketal formulation represents a significant 
contribution to the field of microparticle vaccine delivery systems, and the methods 
developed here can be applied to other areas such as intracellular delivery of enzymes, 
plasmid DNA, or interfering RNA. 
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CHAPTER 4 
EFFICACY OF MICROPARTICLE VACCINES CONTAINING 
OVALBUMIN AND IMMUNOSTIMULATORY AGENTS 
 
4.1  Introduction 
In Specific Aim 3, the objective was to demonstrate the efficacy of model vaccine 
formulations based on the PEG-polylysine cross-linked micelles and polyketal 
microparticles, using in vitro and in vivo protocols.  The cross-linked micelles and 
polyketal microparticle vaccines are designed to deliver protein antigen and TLR-
inducing adjuvants to the phagolysosomes of dendritic cells, where the vaccine 
components will induce activation of DCs and cross-priming of cytotoxic T lymphocytes.  
The adjuvants consisted of TLR agonists including CpG-DNA, MPL, and poly(I:C).  
These adjuvants are capable of stimulating the innate immune response within antigen-
presenting cells (APCs), leading to secretion of inflammatory cytokines such as Type I 
interferons, tumor necrosis factor (TNF)-α, and interleukin (IL)-6, IL-10, and IL-12, as 
well as upregulation of costimulatory surface molecules such as CD80 and CD86 
(Verdijk 1999, Alexopoulou 2001, Loré 2003, Napolitani 2005, Gautier 2005). 
Our working hypothesis was that encapsulation of antigen and TLR agonists in a 
vaccine delivery formulation would enhance the cross-priming of CTLs, in comparison to 
administration of soluble antigen and adjuvant.  To test this hypothesis, we used an in 
vitro dendritic cell-OT1 splenocyte co-culture system and an in vivo immune response 
model.  The experimental protocols are designed to measure the ability of vaccine-treated 
antigen-presenting cells (APCs) to cross-prime cytotoxic T lymphocytes (CTLs).  In the 
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in vitro test, murine splenic dendritic cells were treated with vaccine formulations and co-
cultured with splenocytes from an OT-1 mouse.  The OT-1 mouse strain expresses a 
transgenic T-cell receptor that recognizes the H-2Kb-restricted ovalbumin peptide 
SIINFEKL presented by major histocompatibility complex (MHC) class I molecules.  
Following the co-culture, the expanded T cells were re-stimulated with the SIINFEKL 
peptide along with a Golgi block to induce production and accumulation of cytokines 
within the cells.  We used an anti-CD8+ surface stain to identify cytotoxic T lymphocytes 
(CTLs) and intracellular cytokine staining for IFNγ, TNFα, and IL-2 to measure T cell 
activation and differentiation.   
These experiments were conducted in collaboration with Dr. Bali Pulendran’s 
laboratory at the Emory Vaccine Center.  Dr. Marcin Kwissa and Dr. Sudhir Kasturi 
made significant contributions to the in vitro and in vivo experiments presented in this 
chapter. 
 
4.2  Experimental Methods 
Preparation of Murine Splenic Dendritic Cells and OT-1 Splenocytes 
 Splenic dendritic cells were expanded by daily intraperitoneal injections of 
C57B16 mice with Flt-3 ligand (20 µg/mouse) for 8 days.  Flt-3 ligand was provided by 
Dr. Robert Mittler at the Emory Vaccine Center.  On day 9, the mice were sacrificed and 
splenocytes were harvested, pooled, and frozen.  Dendritic cells were isolated from 
thawed splenocytes using a MACS cell sorter with anti-CD11c magnetic beads, prior to 
cross-priming experiments.  OT-1 splenocytes were obtained by harvesting total 
splenocytes from a C57BL/6-Tg (OT-1) RAG<tm1Mom> mouse.  All animal work was 
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performed under protocols approved by the Institutional Animal Care and Use 
Committee at Emory University. 
 
Dendritic Cell Cross-Priming of CD8+ T Cells 
 Dendritic cell-CD8+ T cell cross-priming experiments were conducted with model 
vaccine formulations based on cross-linked copolymer micelles and polyketal 
microparticles.  A schematic of the in vitro protocol is shown in Figure 4.1.  In this 
procedure, Flt-3 CD11c+ dendritic cells at 1.5 x 105 cells/well were treated with vaccine 
formulation in RPMI medium in a 96-well U-bottom plate.  The micelle formulations 
were added at concentrations ranging from 0.1 to 1 µg/mL ovalbumin, 0.1 to 2 µg/mL of 
CpG-DNA, and/or 0.1 to 2 µg/mL of poly(I:C).  Polyketal and polyketal/PLGA hybrid 
microparticles were added at concentrations ranging from 0.005 to 1 µg/mL of 
ovalbumin.  Control wells were treated with corresponding concentrations of soluble 
ovalbumin and adjuvants.  After 4 or 5 hours of incubation at 37°C, cells were washed 
twice with PBS, and co-cultured with OT-1 splenocytes for 88 hours at 37°C.  In one 
variation, the OT-1 splenocytes were sorted for CD8+ cells before adding to the DCs.  
Cells were then given fresh culture medium containing 5 µg/mL Brefeldin A and 1 
µg/mL ovalbumin-specific MHC class I-restricted peptide (SIINFEKL) and cultured for 5 




In Vivo Vaccine Efficacy of Micelle-Based Vaccine 
The in vivo efficacy of micelle-based vaccine formulations was evaluated using a 
prime-boost study or a single-injection study in B6 mice.  Mice were vaccinated with 
micelles containing 2 to 20 µg of ovalbumin and 2 to 20 µg of CpG-DNA.  For the prime-
boost study, injections were performed on days 0 and 36, and blood was collected on 
days 6, 12, 28, 42, 48 and 58.  PBMCs were isolated using Histopaque®-1077 Hybri-
Max™ solution and restimulated with SIINFEKL peptide for 6 hours and stained as 
described below.  For the single injection study, mice were injected on day 0 and 





















Figure 4.1  In vitro protocol for dendritic cell cross-priming of OT-1 splenocytes. 
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In Vivo Vaccine Efficacy of Polyketal-Based Vaccine 
The in vivo efficacy of polyketal-based vaccine formulations was evaluated using 
a single-injection, 7 day study in B6 mice.  Mice were vaccinated with polyketal or 
polyketal/PLGA hybrid microparticles containing 20 to 50 µg of ovalbumin and 10 to 25 
µg of adjuvant, including MPL, CFA, and poly(I:C).  On Day 7, blood was collected, the 
mice were sacrificed, and spleens and draining lymph nodes were harvested.  Peripheral 
blood mononuclear cells (PBMCs) were isolated using Histopaque®-1077 Hybri-Max™ 
solution.  Spleen cells and lymph node cells were recovered by gentle grinding in a 
plastic strainer. 
 
Intracellular Cytokine Staining and Flow Cytometry 
 Intracellular cytokine staining and surface CD8a staining was performed 
following manufacturer’s protocol.  Cells were centrifuged and resuspended in 100 µL of 
FACS staining buffer (PBS + 5% FBS) containing a 1:200 dilution of Fc block (Anti 
CD16/32, 2.4G2) and a 1:66 dilution of anti-CD8 antibody and stained for 30 min at 4°C.  
Cells were washed twice with 150 µL of FACS staining buffer and then fixed and 
permeabilized using BD Cytofix/Cytoperm solution (BD) for 15 min at 4°C.  Cells were 
washed twice with Perm Wash buffer and stained for IFNγ, IL-2, and TNFα for 30 min at 
4°C.  Cells were washed twice with Perm Wash buffer and once with FACS staining 
buffer and resuspended in 250 µL of FACS staining buffer.  Flow cytometry was 
performed on a FACSCaliburTM  system and analyzed using FlowJo software.  Cells were 
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gated on forward/side scattering (live cells) and CD8a (surface stain), and populations 
were analyzed for intracellular cytokines IFNγ, IL-2, and TNFα (Figure 4.2) 
 
 
4.3  Results 
Efficacy of Cross-Linked Micelle Vaccine Containing Ovalbumin and CpG-DNA 
(June 2005 batch) 
In Vitro Cross-Priming of CD8+ Splenocytes by Ova/CpG Micelles  
 The in vitro cross-priming experiment was conducted with micelles containing 
0.5 mg/mL each of ovalbumin and CpG-DNA.  In one experiment, Flt3-expanded 
dendritic cells were pulsed with the micelle vaccine and then co-cultured with total OT-1 
splenoctyes.  At a dosage of 1 µg/mL, the micelles enhanced the cross-priming of CD8+ T 
cells, as measured by the percentage of IFNγ-producing CD8+ T cells (Figure 4.3).  Also, 
the adjuvant CpG-DNA boosted the efficacy of the micelle formulation at this dosage. 
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Figure 4.4.  In vitro cross-priming of CD8+ T cells by micelles containing 
ovalbumin and CpG-DNA.  Vaccine-pulsed dendritic cells were co-cultured with 
CD8+ OT-1 splenocytes. 










Figure 4.3.  In vitro cross-priming of CD8+ T cells by micelles containing 
ovalbumin and CpG-DNA.  Vaccine-pulsed dendritic cells were co-cultured with 
total OT-1 splenocytes. 
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 In a separate experiment, the vaccine-pulsed DC were co-cultured with CD8+ 
sorted OT-1 splenocytes; i.e., the cell population was devoid of CD4+ helper T cells.  As 
shown in Figure 4.4, the micelle formulation containing ovalbumin and CpG-DNA 
induced a strong CD8+ T cell response at the 1 µg/mL dosage.  This suggests that the 
vaccine formulation bypasses the requirement for CD4+ T cells in stimulating a CD8+ T 
cell reponse. 
   
In Vivo Prime-Boost Vaccination with Ova/CpG Micelles  
 A 58-day prime-boost vaccination study was conducted with the June 2005 batch 
of ovalbumin/CpG-DNA micelles.  The results in Figure 4.5 show a strong CD8+ T cell 
response at 6 days after the prime injection and 6 to 12 days following the boost 
injection.  The fact that the boost response was longer-lasting than the prime response 
Figure 4.5.  In vivo prime-boost vaccination by micelles containing ovalbumin and 
CpG-DNA.  Mice were vaccinated on Day 0 and Day 36. 




























suggests that memory T cells were generated by the first injection.  The 
micelle(Ova/CpG) vaccine formulation had enhanced efficacy in comparison to the 
soluble Ova/CpG control.  Interestingly, the micelle(Ova) formulation had a decreased 
boost response, which suggests tolerance due to the lack of an immunostimulatory TLR 
agonist.  
 
Efficacy of Cross-Linked Micelle Vaccine Containing Ovalbumin, CpG-DNA, and 
Poly(I:C) (Sept 2005 batch) 
In vitro cross-priming of CD8+ splenocytes by Ova/CpG/poly(I:C) micelles  
 Micelles containing ovalbumin, CpG-DNA, and poly(I:C) were evaluated using 
an in vitro DC-OT1 co-culture assay.  The co-culture used either total OT-1 splenocytes 
or CD8+ sorted OT-1 splenocytes.  Figure 4.6 shows the number of CD8+ cells that were 
positive for intracellular IFNγ, as a percentage of total CD8+ cells.  In the control groups, 
the addition of either soluble TLR agonist CpG-DNA or poly(I:C) enhances IFNγ 
production as compared to Ova alone.  The Ova/CpG micelle showed an increased 
response versus soluble Ova/CpG in stimulating CD8+ purified OT-1 splenocytes. 
 
In vivo cross-priming of CD8+ splenocytes by Ova/CpG micelles 
 Because the efficacy of the Sept. 2005 batch was not a strong as the June 2005 
batch, the two batches were compared side-by-side using a 7 day in vivo assay.  In this 
experiment,  the Sept. 2005 batch in general had a weaker response for in vivo activation 
of PBMCs (Figure 4.7).   The large variability between micelle batches eventually led us 




Figure 4.6.  In vitro cross-priming of CD8+ T cells by micelles containing 
ovalbumin, CpG-DNA, and poly(I:C).  Vaccine-pulsed dendritic cells were co-
cultured with total OT-1 splenocytes (left) or CD8+ OT-1 splenocytes (right). 
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Figure 4.7.  In vivo cross-priming of CD8+ T cells by micelles containing 
ovalbumin and CpG-DNA.  PBMCs were stained for IFNγ, TNFα, or SIINFEKL 
tetramer. 
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Efficacy of Hybrid Polyketal/PLGA Vaccine Containing Ovalbumin and MPL 
In Vitro OT-1 Cross-Priming of CD8+ Splenocytes by Ovalbumin/MPL Vaccine 
 Microparticles containing ovalbumin were prepared by double emulsion method 
with a blend of polyketal and PLGA.  MPL was co-encapsulated with Ova or was 
encapsulated alone using a single emulsion.  As controls, Ova and MPL were 
administered in soluble form.  Figure 4.8 shows the in vitro cross-priming of OT-1 
splenocytes, in terms of IFNγ+ cells as a subset of CD8+ cells.  The Ova dosages ranged 
from 0.005 to 0.5 µg/mL for the microparticle groups and from 0.005 to 50 µg/mL for the 
soluble Ova group.  This experiment demonstrates that encapsulation of ovalbumin in 
polyketal-based microparticles dramatically enhances the efficacy as compared to soluble 
ovalbumin.  The addition of MPL in the same particle, or in a separate particle, slightly 
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Figure 4.8.  In vitro cross-priming of CD8+ T cells by hybrid polyketal/PLGA 
microparticles containing ovalbumin and MPL. 
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In Vivo Cross-Priming of CD8+ T cells by Ovalbumin/MPL Vaccine 
 A 6-day vaccine efficacy study in mice was conducted with vaccine formulations 
containing ovalbumin and MPL.  Hybrid polyketal/PLGA microparticles were prepared 
with Ova or MPL in separate particles, or Ova + MPL combined in the same particle 
batch.  Figure 4.9 shows the cross-priming of PBMCs, presented in terms of IFNγ+ cells 
as a subset of CD8+ cells.  The results show that delivery of ovalbumin and MPL in 
separate microparticles enhances the CD8+ T cell response over the controls.  
Interestingly, the combined Ova/MPL particle did not have a strong response.  
 
 
Figure 4.9.  In vivo cross-priming of CD8+ T cells by hybrid polyketal/PLGA 
microparticles containing ovalbumin and MPL. 














Efficacy of Polyketal-based Vaccine Containing Ovalbumin and Poly(I:C) 
In Vitro OT-1 Cross-Priming of CD8+ Splenocytes by Ovalbumin/poly(I:C) Vaccine 
 In this experiment, polyketal microparticles containing ion-paired ovalbumin and 
poly(I:C) were tested in vitro at dosage levels of 0.01, 0.1, and 1 µg/mL ovalbumin and 
0.005, 0.05, and 0.5 µg/mL poly(I:C), respectively.  An example of the flow cytometry 
gating is shown in Figure 4.10, for the lowest dosage groups.  Figures 4.11, 4.12, and 
4.13 show the levels of IFNγ, TNFα, and IL-2, respectively, for all three vaccine dosage 
levels.  All results are presented as the percentage of CD8+ cells that are positive for the 
particular cytokine.  The IFNγ results in Figure 4.11 indicate that at dosage levels of 0.01 
and 0.1 µg/mL ovalbumin, the polyketal microparticles containing ovalbumin and 
poly(I:C) induced significantly higher levels of IFNγ+ T cells than ovalbumin-containing 
microparticles or soluble ovalbumin/poly(I:C).  Notably, the 0.01 µg/mL dosage of 
ovalbumin/poly(I:C)-containing microparticles induced a stronger IFNγ+ T cell response 
than a 10-fold higher dose (0.1 µg/mL) of ovalbumin microparticles.  At the lowest dose 
(0.01 µg/mL), the co-delivery of antigen and TLR3 agonist also significantly enhanced 
the generation of TNFα+ and IL-2+ cells when compared the control formulations 
(Figures 4.12 and 4.13).  The TNFα+ and IL-2+ cell levels induced by the 
ovalbumin/poly(I:C) microparticles at the 0.01 µg/mL dosage were slightly greater than 
that of the ovalbumin microparticles at a 10-fold higher dosage (0.1 µg/mL) (Figures 4.12 
and  4.13).  This was the second of two identical experiments with independent batches 
of polyketal, ion-pairing, and microparticles.  The second batch performed slightly better 
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than the first batch, mostly likely due to better particle dispersion, but both had similar 
trends. 
 
In Vivo Cross-Priming of CD8+ T cells by Ovalbumin/poly(I:C) Vaccine 
 In this single experiment, polyketal microparticles containing ion-paired 
ovalbumin and poly(I:C) were tested in vivo at dosage levels of 20 µg/mouse ovalbumin 
and 10 µg/mouse poly(I:C).  Figure 4.14 shows the percentage of cytokine-producing 
CD8+ T cells from PBMCs, spleen cells, and lymph node cells.  Both vaccine groups 
(soluble and microparticle formulations) showed an increase in levels of CD8+ T cell 
activation compared to untreated mice; however, there was no significant difference 





Figure 4.10.  In vitro DC-OT1 cross-priming by polyketal(Ova-poly(I:C)) vaccine 
at 0.01 µg/mL Ova; flow cytometry scatter plots for CD8+IFNγ+ cells. 
Medium only Soluble Ova Soluble Ova+poly(I:C) 
PKN(Ova) PKN(Ova+poly(I:C) 
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Figure 4.11.  In vitro DC-OT1 cross-priming by polyketal(Ova-poly(I:C)) vaccine; 
percentage of IFNγ-producing CD8+ cells, n = 4 wells per group. 
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Figure 4.12.  In vitro DC-OT1 cross-priming by polyketal(Ova-poly(I:C)) vaccine; 
percentage of TNFα-producing CD8+ cells, n = 4 wells per group. 
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Figure 4.13.  In vitro DC-OT1 cross-priming by polyketal(Ova-poly(I:C)) vaccine; 
percentage of IL-2-producing CD8+ cells, n = 4 wells per group. 
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Figure 4.14.  In vivo cross-priming of CD8+ T cells by polyketal(Ova-poly(I:C)) 
vaccine. Data is shown as mean plus/minus standard deviation for n = 2 (untreated) 
or n = 4 (vaccine groups). 
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4.4  Discussion 
 Our objective in this study was to demonstrate that a vaccine delivery system 
could be developed which would enhance the cytotoxic T lymphocyte response of model 
vaccines containing protein antigen and immunostimulatory adjuvants.  The initial 
experiments were conducted using the PEG-PLTP crosslinked micelle with ovalbumin 
antigen and CpG-DNA (TLR9 agonist).  One particular batch of this micelle formulation 
showed a strong level of CTL cross-priming in vitro and in vivo; however, later batches 
could not reproduce the same level of dendritic cell uptake or CTL cross-priming.  
Possible causes were identified, such as differences in the PEG-PLL degree of 
polymerization or micelle degree of cross-linking, however efforts to pinpoint the root 
cause(s) of the batch-to-batch variation were unsuccessful.  Through the process of 
improving the robustness of the micelle formulation, the SPDP-ovalbumin modification 
and step-wise crosslinking method were introduced, and characterization of these 
micelles demonstrated a high level of encapsulation and retention of ovalbumin and CpG-
DNA, as presented in Chapter 2.  Despite these improvement to the formulation, the 
micelles showed variable enhancement of uptake by DCs, and therefore we pursued solid 
microparticle formulations as an alternative. 
 Microparticle-based vaccine formulations were initially prepared by Sudhir 
Kasturi of the Pulendran laboratory using the polyketal with a double emulsion (water-
oil-water) to encapsulated ovalbumin protein and TLR agonists.  The double emulsion 
process yielded low encapsulation efficiency for ovalbumin, which was attributed to the 
material properties of the polyketals developed at the time.  It was believed that the low 
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molecular weight of the polyketals resulted in less polymer entanglement which allowed 
protein to escape from the inner water phase to the external water phase in the double 
emulsion.   Therefore, polyketal/PLGA blends were pursued, which would provide the 
pH-sensitivity of the polyketal along with the higher molecular weight of the PLGA.  
Hybrid polyketal/PLGA microparticles were prepared at polymer blend ratios of 50/50 
and 25/75, encapsulating ovalbumin and MPL. 
 In subsequent work with double-stranded RNA as the adjuvant, it was deemed 
necessary to use a pure polyketal microparticle, which did not have acidic degradation 
products that might be deleterious to the encapsulated RNA.  In order to encapsulate 
dsRNA and ovalbumin in a polyketal microparticle, we utilized the technique of ion-
pairing to create hydrophobic complexes that could be encapsulated via a single emulsion 
method.  Through this process, polyketal microparticles were formulated with ovalbumin 
and poly(I:C), and the efficacy of this formulation was tested using the in vitro DC-OT1 
assay and in vivo testing in mice. 
Our results demonstrate that the polyketal microparticles and PK/PLGA hybrid 
microparticles containing ovalbumin and TLR agonists are highly effective at cross-
priming CD8+ splenocytes in a DC/OT-1 co-culture system, and in vivo testing of the 
PK/PLGA hybrids showed that a single injection was capable of generating high levels of 
IFNγ+ CTLs.  The in vitro experiments with pure polyketal microparticles containing ion-
paired ovalbumin and poly(I:C) showed that at the lower dosages, the microparticles 
significantly enhanced CD8+ T cell cross-priming as compared to control groups with 
soluble antigen and adjuvant, as shown by high levels of IFNγ-, TNFα-, and IL-2-
producing cells.  The preliminary in vivo results with the ovalbumin/poly(I:C) 
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microparticles did not show any enhancement over the soluble control.  A similar result 
was seen at the highest dosage tested in vitro, which suggests that a lower dosage would 
be more effective in vivo. 
The in vitro tests for the polyketal-formulated Ova/poly(I:C) vaccine showed that 
the microparticles were highly effective at the lower dosages.  For example, the 
polyketal-formulated Ova/poly(I:C) vaccine achieved a higher IFNγ+ CTL response at 
0.1 µg/mL antigen than that seen with a 10-fold higher dose of soluble antigen/adjuvant 
(Figure 4.11).  This dose-sparing effect is seen as an advantage of microparticle-based 
protein vaccines because it enables higher production volumes of the vaccine in the case 
of an epidemic.  Further studies are warranted to examine the effects of dosage and 
combinations of different TLR agonists. 
The strong response even at low doses of antigen can be attributed to the rapid 
simultaneous delivery of antigen and TLR ligand to the phagosomes of dendritic cells.  
The pH-dependent hydrolysis exhibited by the polyketal family enables tuning of the 
hydrolysis kinetics to achieve rapid polymer degradation at lysosomal pH.  The 
copolyketal (PK3) used in this study has a hydrolysis half-life on the order of 1 to 2 days 
at pH 4.5.  This is within the timeframe that antigen presentation and cross-priming of 
CTLs occurs in vivo.  The results are consistent with reported studies that show a strong 
TH1-biased adaptive immune response through activation of TLRs 3, 4, and 9.  For 
example, DCs treated with TLR agonists have been shown to express type I interferons 
(IFN-α and IFN-β), which promote a local antiviral response in infected cells, and pro-
inflammatory cytokines such as interleukin (IL)-12p70 and IL-6 (Verdijk 1999, 
Alexopoulou 2001).  The cytokines induced by TLR 3, 4, and 9 stimulation promote a 
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TH1 bias and antigen-specific cross-priming of CTLs (Lore 2003, Schulz 2005, Zaks 
2006). 
An important feature of the polyketal(ovalbumin/poly(I:C)) formulation is that 
rapid degradation at lysosomal pH allows for delivery of the poly(I:C) at the site of TLR3 
engagement.  TLR3 is an endosomal receptor with its dsRNA binding site facing the 
interior of the endosome.  After the polyketal particles are phagocytosed and the 
phagosome is acidified, the pH-sensitive polyketal should undergo rapid degradation and 
release poly(I:C) into the phagolysosome, where it can be recognized by TLR3.  
Furthermore, it has been shown that TLR3 interacts with poly(I:C) in a narrow pH 
window (pH 5.7 to 6.7) (de Bouteiller 2005); thus, as the pH of the phagosome is lowered 
from its initial level of pH 7.4, the accelerated degradation of the polyketal should allow 
for poly(I:C) to be released and engage TLR3 in the phagolysosome.  We believe that the 
property of tunable, pH-sensitive degradation of polyketals makes this family of 
polymers well suited for delivery of ligands for endosomal TLRs, in particular TLR3. 
The polyketal-based ovalbumin/TLR agonist vaccine formulations induce strong 
CD8+ T cell responses, which indicates that antigenic peptides are presented by MHC-I 
molecules.  This is consistent with reports in the literature that dendritic cells present 
phagocytosed exogenous protein antigen on MHC-I molecules.  For example, reports 
have shown that ovalbumin conjugated to iron oxide beads is presented by bone marrow-
derived DCs on MHC-I molecules (Shen 1997), and conjugates of ovalbumin and CpG-
DNA induce T-helper cell-independent activation of CTLs (Cho 2000).  Because MHC-I 
molecules originate in the endoplasmic reticulum, the processing of antigens trafficked 
through the endosomal-phagosomal system relies on a mechanism which brings the 
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antigen in contact with MHC-I processing machinery.  While the exact processes have 
not been determined, various cellular mechanisms have been proposed in which protein 
antigens or MHC-I molecules are transported between intracellular compartments 
(Groothuis 2005).   
An alternate pathway by which phagosomal antigen may access the MHC-I 
processing machinery is through antigen escape from the lysosome into the cytosol.  This 
would enable the antigen to be processed and loaded onto MHC-I platforms in the same 
manner as endogenous proteins.  In the case of microparticles prepared with CTAB as a 
hydrophobic ion-pairing agent, phagolysosome destabilization may occur as a result of 
interaction of CTAB, a cationic surfactant molecule, with the anionic endosomal 
membrane.  Phagolysosome rupture may also occur due to the osmotic pressure 
imbalance resulting from rapid degradation of the polyketal microparticles into numerous 
small molecules within the phagolysosome.  This mechanism has been proposed with 
other biodegradable delivery vehicles as a means of antigen escape from the endosome to 
the cytosol to achieve MHC-I presentation (Shen 2006, Standley 2007).  Thus, while 
various controlled mechanisms are thought to be involved in endosome-derived antigen 
being presented on MHC-I platforms, alternate pathways involving phagolysosome 
rupture and antigen escape may contribute to MHC-I processing of ion-paired ovalbumin 
released from polyketal microparticles. 
In conclusion, we have demonstrated the development of novel vaccine delivery 
systems for protein antigen and TLR-inducing adjuvants.  The cross-linked micelle has 
been shown to be capable of high efficiency encapsulation of protein, DNA, and RNA; 
however, significant batch-to-batch variation was observed with regard to DC uptake and 
 87
CTL cross-priming.   The issue of low uptake would need to be addressed, perhaps 
through the addition of a targeting ligand, to realize the potential of the cross-linked 
micelle as a vaccine delivery vehicle.  Solid microparticles based on pH-sensitive 
polyketals were shown to have enhanced uptake by DCs, and various microparticle 
formulations were prepared using a polyketal/PLGA hybrid with a double emulsion, or a 
polyketal with ion-pairing and a single emulsion method.  We have demonstrated that the 
polyketal-based vaccine formulations enhance the ability of dendritic cells to cross-prime 
cytotoxic T lymphocytes in vitro, as evidenced by production of IFN-γ, TNF-α, and IL-2.  
Very low doses of antigen and adjuvant are required, which can be attributed to the rapid 
intracellular release from the polyketal-based microparticles.  Additionally, 
polyketal/PLGA hybrid formulations containing ovalbumin and MPLA have shown 
significant enhancement of CTL priming in mice. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1  Conclusions 
 In completing these specific aims, we have demonstrated the development of two 
versatile delivery systems for protein and nucleic acid biotherapeutics.  The first system 
is a self-assembling block copolymer micelle that encapsulates proteins and nucleic acids 
via electrostatic interactions and disulfide cross-linking.  The micelle has the advantages 
of high encapsulation efficiency and flexible batch scaling, and has a size range of 50-
150 nm.  The second system is a solid nanoparticle composed of a pH-sensitive 
biodegradable polyketal which is capable of encapsulating hydrophobic compounds as 
well as proteins and nucleic acids.  The polyketal particles (300 nm to 3 µm) have high 
uptake by phagocytic cells, and the polyketal degrades into non-acidic molecules that are 
not detrimental to encapsulated biotherapeutics.  The micelles and microparticles were 
evaluated for their efficacy as protein vaccine delivery vehicles, using ovalbumin as a 
model antigen and various TLR agonists as immunostimulatory adjuvants.  These 
experiments focused on the cross-priming of CD8+ T cells by DCs treated with vaccine 
formulations.  The cross-linked micelles served as a proof-of-concept for the 
enhancement of CD8+ T cell priming by encapsulation of ovalbumin (protein antigen) 
along with CpG-DNA (TLR9 agonist) and/or poly(I:C) (TLR3 agonist) in a delivery 
vehicle; however, variability in DC uptake and activation was observed among micelle 
batches.  Solid microparticles based on pH-sensitive polyketals were developed, which 
improved the uptake by phagocytic cells.  We demonstrated that polyketal-based 
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microparticle formulations containing ovalbumin and the TLR4 agonist MPL were 
capable of enhancing CD8+ T cell responses in vitro and in vivo, in comparison to 
soluble formulations.  We also showed that polyketal microparticles could be prepared 
with hydrophobic ion-paired ovalbumin and poly(I:C) (TLR3 agonist), and that this 
vaccine formulation elicited strong CD8+ T cell responses in vitro at low antigen doses.  
From these results it can be concluded that the polyketal-based microparticles, in 
conjunction with the hydrophobic ion pairing technique, have significant potential as a 
delivery system for protein/TLR-agonist vaccines.  
 
5.2  Future Directions 
 Several areas of future research have been considered to improve the functionality 
of the cross-linked micelles and polyketal microparticles, and to explore more effective 
protein-based vaccine formulations. 
 
1.  Further Development of Cross-linked Micelle Delivery System 
a)  Add a targeting ligand to improve uptake by DCs or other target cells.  A simple 
method would be to conjugate a targeting peptide to the PEG-PLTP polymer by including 
a single cysteine residue at one end of the peptide and adding the peptide prior to the 
cross-linking step.  Another method would be to conjugate the targeting ligand to the 
distal end of the PEG chain.  This would require a heterobifunctional PEG with 
conjugation chemistry that is orthogonal to that used in cross-linking the interior of the 
micelle.  For example, the click reaction between an alkyne and a azide could be used to 
attach the targeting ligand to free end of the PEG chain. 
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b)  Synthesize a PEG-poly(Lys) dendrimer.  A PEG-poly(Lys) dendrimer could be 
synthesized in a controlled manner, as opposed to the ring-opening polymerization 
currently used for the PEG-poly(Lys).  This would produce a polymer with narrow 
distribution, and thus would improve the uniformity of the micelles.  The dendrimer 
could be synthesized using Fmoc protecting groups on the Lysine, similar to the methods 
used in solid-state peptide synthesis.  Preliminary experiments would be needed to 
demonstrate that the dendrimer block could complex proteins and nucleic acids as 
effectively as a linear polymer chain.   
c)  Develop non-reversible cross-linking chemistry.  An alternative cross-linking scheme 
could be used for extracellular applications where it might be desired to keep the micelle 
intact for an extended time.  One possible application is enzyme-cleavable prodrug 
therapy for cancer.  Micelles loaded with enzyme would be delivered to the tumor site 
due to the enhanced permeability and retention effect (EPR), and the enzyme, which is 
active inside the core of the micelle, would convert the prodrug to the active drug at the 
tumor site. 
d)  Develop alternative method of conjugating proteins in the micelle core.  The SPDP 
conjugation has been demonstrated for ovalbumin and catalase, both of which are 
relatively inexpensive proteins.  If this process were to be scaled down, there would be 
some loss in material in the conjugation and purification steps.  Thus, it would be 
preferred to use a method such as glutathione-GST affinity to bind a GST fusion protein 




2.  Improvements to Polyketal Microparticles 
a)  Improve microparticle fabrication process.  Optimization of the homogenization, 
solvent evaporation, and particle washing steps are needed to increase the particle yield. 
b)  Prevent aggregation of precipitated microparticles.  Aggregation has been an issue 
with microparticles following the washing and lyophilization steps.  This may be 
improved by analyzing the effects of the size and material properties of the polyketal 
microparticles, and modifying the chemistry or process parameters to reduce aggregation. 
 
3.  Improvements to Vaccine Formulations 
a)  Investigate synergy between TLR agonists.  Evidence of synergy between TLR 
agonists has been reported in the literature (Napolitani 2005, Gautier 2005, Theiner 
2008).  The microparticle delivery system provides an excellent platform to explore 
various combinations of TLR agonist delivered simultaneously with protein antigen.  A 
systematic evaluation of combinations of agonists for TLRs 3, 4, 7, and 9 could be 
performed using in vitro DC-splenocyte cross-priming and in vivo T cell proliferation 
models. 
b)  Optimize dosage of antigen and adjuvant.  In vitro and in vivo results have suggested 
that high doses of microparticle-formulated antigen/adjuvant are not optimal.  Various 
dosages should be explored to achieve the highest CTL response, and also to determine if 
the benefits of dose-sparing can be realized.  Furthermore, experiments should be 
conducted with different ratios of antigen and adjuvant to optimize the dosages. 
c)  Delivery of siRNA for IL-10.  The hydrophobic ion paring technique has been used to 
encapsulate siRNA in polyketal microparticles, and TNFα siRNA particles enhance the 
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suppression of TNF-α in RAW264.7 cells (Sungmun Lee, manuscript in preparation).  
We have also been interested in suppressing IL-10 for vaccine applications (Igietseme 
2000, Liu 2004). Preliminary experiments, however, suggest that siRNA-mediated IL-10 
suppression may be difficult to ascertain due to the non-specific stimulation induced by 
dsRNA through TLR3 or MDA-5.  As an alternative, IL-12 expression can be measured, 
to determine if IL-10 siRNA is more effective at increasing IL-12 production than 
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